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Cancer is the leading cause of death in the developed world and the second 
leading cause of death in the developing world, with approximately 13% of all 
deaths each year (Jemal, et al., 2011; WHO, 2006). Cancer cells, by definition, 
grow and proliferate in defiance of normal controls and are able to invade 
surrounding tissues and colonize distant organs. Cancer cells are thought to 
originate from a single cell that has experienced an initial mutation, but the 
progeny of this cell must undergo many further changes, requiring numerous 
additional mutations and epigenetic events, to become cancerous.  
Tumor progression usually takes many years and reflects the operation of a 
Darwinian-like process of evolution, in which somatic cells undergo mutation 
and epigenetic changes accompanied by natural selection (Alberts et al., 2008). 
The sequence of events underlying tumor progression and metastasis is 
subjected to perpetual elucidations and it is hoped that the study of cancer 
associated-molecules may provide data to better understand the cancer disease 
from the original disruption to the development of clinical symptoms.  
Cancers are classified in two ways: by the type of tissue in which the cancer 
originates and by the site in the body, where the cancer first develops 
(www.cancercenter.com). 
 
1.1 Pancreatic adenocarcinoma 
Adenocarcinoma is a cancer that originates from an epithelium in glandular 
tissue. The pancreatic adenocarcinoma is the most common type of pancreatic 
cancer, accounting for 95% of pancreatic tumors. Less common types of 
pancreatic cancer include neuroendocrine or islet cell tumors. Pancreatic cancer 
is the fourth most common cause of cancer death across the world (Hariharan, 
2008). Patients diagnosed with pancreatic cancer typically have a poor prognosis 
which is attributable to the fact that most patients have metastatic disease at the 
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time of diagnosis (Merl et al., 2010). Common symptoms include: pain in the 
upper abdomen, loss of appetite and/or nausea and vomiting, significant weight 
loss, painless jaundice, trousseau sign (in which blood clots form spontaneously 
in the portal blood vessels), diabetes mellitus, clinical depression, symptoms of 
pancreatic cancer metastasis (Pannala et al., 2009; Carney et al., 2003). 
The risk factors for pancreatic cancer include: cigarette smoking (approximately 
30%), diet (a diet high in meat and fats increase pancreatic cancer risks), 
diabetes mellitus, chronic pancreatitis, family history, age, male sex, 
Helicobacter pylori infection (Raderer et al., 1998; Stolzenberg et al., 2001; 
Michaud et al., 2007). Besides surgery, single agent gemcitabine is widely 
accepted as first-line therapy, common second-line chemotherapy regimens 
include oxaliplatin and 5-FU/leucovorin gemcitabine and oxaliplatin, oxaliplatin 
and capecitabine, and irinotecan-oxaliplatin (Brus and Saif, 2010).  
The most frequently mutated oncogene in pancreatic cancer is KRAS2 which is 
mutated in >95% of pancreatic cancer (Hruban et al., 1993). The KRAS2 gene is 
located on chromosome arm 12p and encodes a membrane-bound guanosine 
triphosphate (GTP)-binding protein. This GTP-binding protein mediates various 
cellular functions, such as proliferation, cellular survival, motility, and 
cytoskeletal remodeling (Hingorani et al., 2003). Mutations in the KRAS2 gene 
are considered to be one of the earliest genetic events in pancreatic 
tumorigenesis (Jones. et al., 2008). Several additional signaling pathways 
downstream from KRAS2, including BRAF-MAPK and PI3K-AKT, may also 
be activated by mutations. 
Three tumor suppressor genes, CDKN2A/p16, TP53, and SMAD4/DPC4, are 
commonly inactivated in pancreatic cancer (Caldas et al.,1994; Wilentz et al., 
2000). These genes are inactivated by different mechanisms such as 
homozygous deletion of both alleles of the gene; intragenic mutation in 1 allele, 
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coupled with loss of the other allele; or promoter hypermethylation (Schutte et 
al., 1997; Ueki et al., 2000). 
Particularly in pancreatic cancer, the tumor microenvironment actively promotes 
invasion and tumor growth through a complex of interactions of different 
cellular components (Krautz et al., 2011). 
 
1.2. Tumor metastasis 
Metastasis formation is a complex process which requires the dissociation of 
tumor cells from the primary tumor, migration through the extracellular matrix, 
penetration through the basal membrane, adaptation to the circulation pressure, 
docking to vascular endothelium, settlement and growth in distant organs (Fidler 
and Radinsky, 1990; Mareel et al., 1991). These processes are responsible for 
~90% of pancreatic cancer deaths in patients (DiMagno et al., 1999). Metastasis 
involves changes in the physical coupling of cells to their microenvironment and 
activation of extracellular proteases (Keleg et al., 2003).  
Several controversial theories exist to explain the organ specificity of metastasis. 
Among them, the homing theory suggests that organs distant to sites of primary 
malignancy actively attract malignant cells via expression of adhesion receptors 
or by secretion of soluble chemotactic factors (Muller et al., 2001). 
Identification of molecular addresses or adhesion receptors on endothelial cells 
in vascular beds of distal organs that specifically trap circulating malignant cells 
supports the active arrest view of the homing theory (Borsig et al., 2002). In 
contrast, the “seed and soil” theory of Stephen Paget in 1889 stated that tumors 
do not metastasize randomly but rather at preferred sites. The formation of 
metastasis depends both on the properties of the tumor cells (the seed) as well as 
the permissive role of the environment (the soil) at the distant site (Fidler, 2003). 
Recently, it has been discovered that primary tumors themselves induce the 
formation of a suitable and appropriate environment in the organ where 
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metastasis will be seeded. Experiments have revealed that before the arrival of 
the metastatic tumor cells to a target organ, like the lungs or the liver, these 
organs are colonized by myelomonocytic cells originating from the bone 
marrow and mobilized by the primary tumor. These cells create an 
inflammatory-like microenvironment similar to the one formed in the primary 
tumor facilitating tumor cell seeding and initial survival in an a priori hostile 
environment. This has led to the concept of the premetastatic niche, whereby a 
special, permissive microenvironment in secondary target organs is induced over 
distance by the primary tumor. Some of the molecular mechanisms contributing 
to the formation of the premetastatic niche have been discovered and include 
mediators of inflammation, such as TNF, interleukins, matrix proteins or matrix-
degrading enzymes (www.unifr.ch/pathology/en/ background/tumormetastasis). 
Tumor invasion encompasses the process of tumor cell penetration or infiltration 
into adjacent tissue. This event is also central to the development of metastasis. 
Loss of junctional contact between adjacent epithelial cells and cell-extracellular 
matrix association are essential prerequisites for tumor cell detachment from the 
primary tumor site (Tawil et al., 1996). It is postulated that migration and 
invasion of cancer cells into surrounding stroma are prevented by cell-cell and 
cell-matrix adhesion molecules. Disruption of these adhesive connections leads 
to increased motility of tumor cells, which detach from the primary lesion. 
Therefore, adhesion molecules on the cell surface play an important role in 
tumor cell migration and regulate the potential to metastasize (Keleg et al., 
2003).  
Metastatic cancer cells may persist as small asymptomatic nodules for prolonged 
periods of time. This condition, also referred to as dormancy, has been reported 
in experimental models and patients. Dormant tumor cells were often observed 
in close proximity to quiescent vessels. This observation led to the hypothesis 
that dormancy is due to insufficient angiogenic capacity of the tumor cells, 
resulting in a state of balance between proliferation and cell death. Induction of 
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angiogenesis in dormant micrometastasis has been proposed as a mechanism 
triggering transition from a dormant metastasis to a growing metastasis. In 
addition, recruitment of bone marrow-derived or inflammatory cells has been 
reported to promote metastasis outgrowth. Thus, like in the primary tumor, 
changes in the microenvironment determine whether and when microscopic 
lesions will eventually grow to form a macroscopic metastasis. This proposed 
mechanism, although it helps to understand why metastases may appear many 
years after the primary tumor has been removed, does not yet explain why 
suddenly angiogenesis is induced and tumor growth is resumed. Nevertheless, 
dormancy is of great clinical relevance since it raises the possibility of 
therapeutic interventions before metastases resume growth (Bogenrieder et al., 
2003).  
 
Figure 1:  Models of metastasis. (a) According to Chambers and co-workers, only a very small 
population of injected cells (2%) form micrometastases, although over 87% are arrested in the liver. 
Furthermore, not all of the micrometastases persist, and the progressively growing metastases that kill 
the mice arise only from a small subset (0.02%) of the injected cells. (b) Muschel and co-workers 
recently proposed a new model for pulmonary metastasis in which endothelium-attached tumor cells 
that survived the initial apoptotic stimuli proliferate intravascularly. Thus, a principal tenet of this new 
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model is that the extravasation of tumor cells is not a prerequisite for metastatic colony formation and 
that the initial proliferation takes place within the blood vessels (Im et al., 2004). (c) The unique 
ability of aggressive tumor cells to generate patterned networks, similar to the patterned networks 
during embryonic vasculogenesis, and concomitantly to express vascular markers associated with 
endothelial cells, their precursors and other vascular cells has been termed „vasculogenic mimicry‟ by 
Hendrix and co-workers (Hess et al., 2006). 
 
1.2.1. Matrix metalloproteinases (MMPs) in metastasis  
Matrix metalloproteinases (MMPs) are a family of highly homologous protein-
degrading zinc dependent endopeptidases. This family currently includes more 
than 25 members that can be divided into collagenases (MMP-1, -8, and -13), 
gelatinases (MMP-2 and 9), stromelysins (MMP-3 and 10), matrilysins (MMP-7 
and 26), and the membrane-type MMPs (MMP14 to 17 and -24, -25). 
Degradation and remodeling of the ECM, including the basement membrane, by 
proteolytic enzymes are essential steps in the process of cancer invasion, intra- 
and extravasation, and colonization at distant sites. Metalloproteases are thus 
important in many aspects of invasion and metastasis, ranging from cell 
proliferation and remodeling of the ECM to angiogenesis and cell migration. 
Most of these processes require a delicate balance between the functions of 
MMPs and ADAMs and tissue inhibitors of metalloproteases (TIMPs). ADAMs 
are named according to their structure, which includes a disintegrin and a 
metalloproteinase domain. ADAMs are membrane integrated proteases that 
regulate the function of a wide range of cell surface proteins by proteolytic 
ectodomain cleavage. Several of the ADAM proteins have alternative names, 
mostly given at their first description due to their preferential target, like 
ADAM17 that is also called TACE for TNF-alpha converting enzyme (Saftig 
and Reiss, 2011). TIMPs are a family of secreted proteins that selectively, but 
reversibly, inhibit metalloproteases in a 1 : 1 stoichiometric manner. During the 
invasive events, TIMPs are expressed primarily by the cancer cells and are 
thought to serve as a regulatory mechanism for fine tuning the activity of 
stromal MMPs, so that the cancer cells can have an active role in determining 
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where and when they invade (Chang and Werb, 2001; Egeblad and Werb, 2002). 
The expression and activity of MMP-2 and MMP-9, two intensively studied 
gelatinases, are frequently elevated in human cancer, which correlates with 
advanced tumor stage, increased metastasis, and poor prognosis (Lubbe et al., 
2006). MMP-3 is known to degrade collagen types III, IV, IX and X, 
proteoglycans, laminin, elastin, and fibronectin (Samnegard et al., 2005). 
MMP14, also known as MT1-MMP, a key MMP that regulates invasion and 
metastasis, plays a dual role in pathophysiological digestion of the ECM through 
activation of proMMP-2 and direct cleavage of substrates such as collagen types 
I, II, and III. Regulated positioning of MMP14 to invadopodia, the specialized 
ECM-degrading membrane protrusions of invasive cells, enables focal 
degradation of ECM during invasion and metastasis (Poincloux et al., 2009). 
Degradation of structural and specialized components of the ECM by MMPs not 
only breaks the barrier that restrains tumor cell dissemination but also generates 
some bioactive fragments (Hua et al., 2011). Upon MMP digestion, the ECM 
also releases biologically active fragments called matrikines, i.e., peptides 
originating from the fragmentation of matrix proteins and presenting biological 
activities (Ducaa et al., 2004). For example, cleavage of laminin-5 γ2 chains by 
MMP-2 and MT1-MMP produces a fragment containing epidermal growth 
factor (EGF)-like motifs that engages EGFR signaling and larger fragments that 
engage integrin signaling, leading to cell migration (Koshikawa et al., 2005; 
Sadowski et al., 2005). The cross-talk between MMPs and other proteases also 
contributes to tumor progression (Hua et al., 2011). MMP-9 can regulate the 
activity of other proteases such as uPA. A recent study reveals that MMP-9 
degrades the serpin protease nexin-1, an inhibitor of uPA. However, the effects 
of nexin-1 on tumor metastasis seem to be controversial. Nexin-1 reportedly 
binds low density lipoprotein receptor-related protein 1 (LRP-1) and stimulates 
extracellular signal-regulated kinase signaling, MMP-9 expression, and 
metastatic spread of mammary tumors (Fayard et al., 2009). The inconsistency 
 8 
of these studies is hard to explain. Given that MMP-9 can be upregulated by 
nexin-1, the degradation of nexin-1 by MMP-9 may represent a negative 
feedback regulation of nexin-1 activity (Xu et al., 2010). 
Except for components of the ECM, there are non-ECM substrates for MMPs 
that include growth factors, kinases, cytokines, chemokines, and receptors (Hua, 
et al., 2011). MMP14 cleaves HB-EGF and removes the NH(2)-terminal 20 
amino acids that are important for binding heparin. The truncated form of HB-
EGF is independent of heparin and exhibits enhanced mitogenic activity 
(Koshikawa et al., 2010). Moreover, MMP14 degrades the Wnt/planar cell 
polarity protein-tyrosine kinase-7 (PTK7), an inhibitor of cell invasion. The 
cleavage of PTK7 by MMP14 leads to an increase in cell invasion and migration 
(Golubkov et al., 2010). Tumor-associated MMP14 sheds RANKL and activates 
src-dependent prostate cancer migration and bone metastasis (Sabbota et al., 
2010). Thus, MMP14 may play pivotal roles in both the growth and metastasis 
of tumor cells (Hua et al., 2011). 
MMPs also have complex roles in angiogenesis. It is known that MMPs can 
promote endothelial cell migration and trigger the angiogenic switch. For 
example, MMP-9 participates in switching angiogenesis by releasing VEGF 
from ECM (Bergers et al., 2000). Furthermore, MMPs increase the 
bioavailability of the pro-angiogenic growth factors vascular endothelial growth 
factor (VEGF), fibroblast growth factor-2 (FGF-2), and TGF-β, which stimulate 
proliferation and migration of endothelial cells. MMP14 regulates VEGF-α 
expression by promoting VEGFR-2 cell surface localization thereby activating 
the VEGFR-2-Src-Akt-mTOR pathway (Ito et al., 2009). However, MMPs may 
have adverse effects on angiogenesis. For example, MMP14-mediated endoglin 
shedding inhibits tumor angiogenesis (Hawinkels et al., 2010). 
Epithelial-mesenchymal transition (EMT) is a key developmental process 
characterized by loss of cell adhesion, repression of E-cadherin expression, and 
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increased cell mobility (Koshikawa et al., 2010). EMT may be essential for 
numerous developmental processes including mesoderm formation and neural 
tube formation. During tumor progression, EMT is often activated to promote 
cancer cell invasion and metastasis. MMPs are important regulators or mediators 
of EMT. MMP-2 is necessary for the EMT that generates neural crest cells and 
plays an essential role inducing epithelial-mesenchymal transformations in the 
avian embryo (Duong and Erickson, 2004). 
The overexpression and elevated activity of MMPs correlate with tumor 
progression. The balance between activated MMPs and their inhibitors such as 
TIMPs may define the net activity of MMPs. Down-regulation of TIMPs may 
result in an increase in the activity of MMPs and the invasive potential of tumor 
cells. Conversely, tumor invasion and metastasis can be inhibited by up-
regulation of TIMPs in tumor cells (Hua et al., 2011). Overexpression of TIMP-
1 inhibits tumor growth and metastasis of melanoma (Khokha, 1994), suppresses 
human gastric cancer metastasis (Watanabe et al., 1996), and prevents oral 
squamous cell carcinoma progression (Wen et al., 1999). Although 
accumulating data demonstrate that TIMPs have tumor-suppressive activities, 
studies also show that TIMPs may play contrasting roles in tumor progression 
(Hua et al., 2011). 
 
1.2.2. Integrins 
Integrins are non-covalently linked heterodimers of alpha and beta subunits 
(Gonzalez-Amaro and Sanchez-Madrid, 1999; Etzioni et al., 1999). They are 
transmembrane proteins that are constitutively expressed, but require activation 
in order to bind their ligand. To date, 15α subunits and 8β subunits have been 
identified. These can combine in various ways to form different types of integrin 
receptors. Integrins exhibit both “outside-in” and “inside-out” signaling 
properties (Coppolino and Dedhar, 2000; Zell et al., 1999). 
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In addition to their roles in adhesion to ECM ligands or counterreceptors on 
adjacent cells, integrins serve as transmembrane mechanical links from those 
extracellular contacts to the cytoskeleton inside cells. The β4 subunit differs 
from all the others; its cytoplasmic domain being much larger, approximatively 
1000 amino acids long instead of around 50, and making connections to 
intermediate filaments instead of to actin (Hynes, 2002). Alterations in α6β4-
integrin-mediated signalling are accompanied by a reduction in cell motility, cell 
invasion, alterations in the organization of the actin cytoskeleton and changes in 
cell shape (Alam et al., 2011). 
 
1.2.3 Hypoxia 
The inner regions of malignant tumors become hypoxic as the tumor grows and 
rapidly expands. Hypoxia is a state where oxygen tension drops below normal 
limits and is a common feature of malignant tumors. Hypoxia is usually defined 
as ≤2% O2, and severe hypoxia (or anoxia) is defined as ≤0.02% O2. However, 
ambient air is 21% O2 (150 mm Hg) and most mammalian tissues exist at 2%–
9% O2 (on average 40 mm Hg) (Bertout et al., 2008). A key regulatory protein 
involved in the cellular adaptive response to hypoxia is hypoxia-inducible 
factor-1 (HIF1) (Vaupel et al., 2004). The hypoxia-inducible factor (HIF) is a 
heterodimeric transcription factor consisting of one of three different oxygen-
sensitive HIFα subunits (HIF1α, HIF2α, and HIF3α) and a common constitutive 
HIFβ subunit. Whereas HIF1αβ and HIF2αβ heterodimers function as 
transcriptional activators of oxygen-regulated target genes, the role of HIF3α is 
less clear, and a short splice variant of HIF3α, termed inhibitory PAS protein 
(IPAS), functions as a transcriptional repressor (Semenza et al., 1999; Wenger, 
2002; Seta et al., 2002). HIF1β is constitutively expressed, but HIF1 has a 
short half life under normoxic conditions and is rapidly degraded. However, 
under hypoxic conditions, HIF1α is stabilized and induces the transcription of a 
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number of downstream target genes involved in physiologic and pathologic 
processes (Semenza, 2002; Maxwell et al., 1997).  
 
1.2.3.1. Regulation of HIF1 
The partial pressure of cellular oxygen is sensed by a family of prolyl 
hydroxylases that covalently modify HIF subunits (Jaakkola et al., 2001). 
Under normoxic conditions, HIFα is hydroxylated; hydroxylation promotes von 
Hippel-Lindau (VHL) tumor suppressor protein binding to HIFα, thereby 
targeting it for proteasomal destruction (Maxwell et al., 1999). Under hypoxic 
conditions, the Prolyl-hydroxylase domain (PHD) activity (and thus HIFα 
hydroxylation) decreases. Thus, the high turnover rate of HIFα subunits enables 
the very rapid accumulation of HIFα under hypoxic conditions (Jewell et al., 
2001). Following a further decrease in oxygen availability, the asparagine 
hydroxylase function of the factor inhibiting HIF (FIH) also becomes impaired, 
resulting in a decrease in HIFα C-terminal hydroxylation. This decrease in C-
terminal HIFα hydroxylation enables the increased recruitment of the p300 and 
CREB binding protein (p300/CBP) transcriptional coactivators, leading to the 
enhanced transcriptional activation of HIF target genes (Mahon et al., 2001; 
Lando et al., 2002). Once the HIFα protein is stabilized, it heterodimerizes with 
the constitutively expressed HIFβ subunit, ARNT (aryl hydrocarbon receptor 
nuclear translocator), to form the heterodimeric transcription factor HIF. HIF 
binds DNA at hypoxia response elements (HRE) and recruits transcriptional 
coactivators such as p300/CBP. Apart from the essential protein-protein 
interaction between HIFα and HIFβ subunits, a multitude of other proteins are 
known to interact with HIFα (Wenger et al., 2005). 
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Figure 2: Control of hypoxia-inducible factor (HIF) by hydroxylation. HIF1α and HIF2α (shown 
generically as HIFα) contain a basic helix–loop–helix PAS DNA binding domain (DBD) and two 
transactivation domains (NTAD and CTAD). When O2 levels are low, HIFα is stable and the NTAD 
and the CTAD are active. At intermediate levels of hypoxia the CTAD, especially of HIF1α, is 
hydroxylated on a conserved asparagine (Asn) residue by factor inhibiting HIF (FIH1). This prevents 
recruitment of the co-activators p300 and CREB-binding protein (CBP). As O2 is more plentiful HIFα 
is hydroxylated on one (or both) of two proline (Pro) residues near the NTAD (for simplicity, only one 
site is shown) by prolyl hydroxlase 2 (PHD2), generating a binding site for the von Hippel-Lindau 
protein (VHL). Recruitment of the VHL ubiquitin (Ub) ligase complex containing elongin C (ELC), 
elongin B (ELB), cullin 2 (CUL2) and RING-box protein 1 (RBX1) leads to the polyubiquitylation 
and proteasomal degradation of HIFα. FIH1 and PHD2 require several cofactors, including 2-
oxoglutarate and reduced iron, and are inhibited by reactive oxygen species (ROS) (Bertout et al., 
2008). 
 
1.2.3.2. The consensus HIF responsive element (HRE) sequence 
Once stabilized and activated, HIF binds to the consensus HRE, which is present 
in the oxygen-regulated elements of 70 known HIF target genes. Microarray 
experiments indicate that far more than 200 HIF target genes might exist; 
however, not all of these genes are likely to be directly regulated by an HRE in 
their regulatory regions. Rather, other HIF-dependent or -independent oxygen-
regulated transcription factors might be responsible for their hypoxic induction. 
A single core HRE is necessary but not sufficient for efficient gene activation in 
response to hypoxia. Although the core HRE is the minimal DNA domain 
required for interaction with HIF, a fully functional HRE usually contains 
neighboring DNA binding sites for additional transcription factors. These 
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transcription factors are not necessarily hypoxia inducible, but they might 
amplify the hypoxic response or confer tissue-restricted activity to an HRE 
(Wenger et al., 2005). For instance, HIF1 cooperates with ATF-1 and CREB-1 
to transcriptionally activate the lactate dehydrogenase A gene (Ebert et al., 
1998; Firth et al., 1995) or with AP-1 binding factors to activate the gene 
encoding vascular endothelial growth factor (VEGF) (Damert et al., 1997).  
 
 
Fig. 3: The consensus core HRE sequence RCGTG (where R is A or G) and flanking nucleotides. 
Relative occurrence of the nucleotide distributions within 108 core HREs indicated as percentage of 
total. Shadowed boxes (light blue) indicate nonrandomly distributed nucleotide compositions, which 
occur mainly at 5′ flanking bases where HIFα subunits contact the DNA. For position −1, only one T 
and two C‟s were identified among 108 core HREs, raising concerns about their physiological 
relevance (Wenger et al., 2005). 
 
1.2.3.3. Mechanisms regulating HIF binding to the core HRE 
Apart from the requirement for cooperation among transcription factors, 
epigenetic effects may also reduce the large number of putative core HREs to 
relatively few functional HREs. Methylation of the CpG dinucleotide 
(containing 5-methylcytosine) plays an important regulatory role in mammalian 
gene expression, contributing to X-chromosome inactivation and genomic 
imprinting, as well as tissue- and developmental stage-specific transcriptional 
regulation. CpG dinucleotides are underrepresented in the mammalian genome 
and are usually methylated if located outside of GC-rich “CpG islands.” The 
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consensus core HRE contains a CpG dinucleotide, thus lowering the number of 
actual HREs found in the genome compared to the frequency of a random 
tetranucleotide sequence. Methylated CpG interferes with transcription factor 
binding to DNA through both direct steric hindrance and the binding of 
repressor proteins (Wenger et al., 2005). It has been reported that HIF binding to 
the core HRE is blocked by 5-methylcytosine (Wenger et al., 1998).  
Oxidative DNA damage caused by ROS might represent another epigenetic 
modification regulating HRE accessibility. Intriguingly, ROS induced in 
response to hypoxia oxidize particular bases within specific DNA sequences of 
the HIF target gene VEGF. The most frequently modified nucleotide is the 
terminal guanine of the VEGF core HRE (ACGTGGG). Because the base 
modifications occur close to, but not directly at the consensus core HRE, 
different HREs are likely to be unequally affected by ROS, providing a means of 
variable modulation of the efficiency of gene-specific transcriptional induction 
(Wenger et al., 1998).  
 
1.2.4. Exosomes  
Exosomes are small membrane vesicles, 30 to 100nm, of endocytic origin that 
are secreted by most cells in culture (Théry et al., 2002). They derive from 
multivesicular bodies, which either fuse with lysosomes or fuse with the plasma 
membrane and release their intraluminal vesicles as exosomes. Thus, exosomes 
share the biochemical characteristics with the internal vesicles of the 
multivesicular bodies (Lakkaraju et al., 2008, Camussi et al., 2010). The 
molecular composition of exosomes reflects their origin from intraluminal 
vesicles. Accordingly, the range of proteins recovered in exosomes is rather 
limited. Exosome preparations do not contain any proteins of nuclear, 
mitochondrial, endoplasmic-reticulum or Golgi-apparatus origin. All of the 
exosomal proteins that have been identified are found in the cytosol, in the 
membrane of endocytic compartments or at the plasma membrane. Besides 
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several common components, exosomes also contain cell type specific proteins. 
Exosomal proteins are functionally active (Théry et al., 2002, Schorey and 
Bhatnagar, 2008, Zöller, 2009). Exosomes also contain mRNA and microRNA, 
which are transferred to the target cell, where they can be translated (mRNA) 
and mediate RNA silencing (microRNA) (Lakkaraju et al., 2008, Valadi et al., 
2007). This process is target cell-specific, such that RNA is transcribed in one 
but not another type of cell (Valadi et al., 2007). Thus, exosomes constitute a 
potent mode of intercellular communication that is important in immune 
response (André et al., 2002; Chaput and Théry, 2011), cell-to-cell spread of 
infectious agents (Schorey and Bhatnagar, 2008) and tumor progression (Zöller, 
2006).  
The mode whereby exosomes interact with their target has not yet been fully 
elucidated. Exosomes can bind to target cells, fuse with the target cell membrane 
or be taken up by the target cell. These modes of interaction are not mutually 
exclusive. It is, however, important to note that the exosome target cell 
interaction is selective. This is very important, as exosomes by the transfer of 
proteins, mRNA and microRNA can severely affect the fate of the target cell 
(Théry, 2011; Mittelbrunn et al., 2011; Valadi et al., 2007). 
 
1.3. The BSp73 tumor model 
The BSp73 tumor was diagnosed as a pancreatic adenocarcinoma in the BDX rat 
strain with a local tumor in the pancreatic tissue and ascitic metastasis. When 
implanting the local tumor subcutaneously, it maintained its local growth 
behavior and grew as a solid tumor at the implantation site (AS). Instead, when 
the tumor cells derived from the ascites were subcutaneously implanted, no local 
growth was observed. Instead, the tumor cells metastasized via the lymphatic 
system to the lung, where they formed thousands of miliary metastases (ASML) 
(Matzku et al., 1985). The highly metastasizing variant ASML showed spherical 
morphology in culture, while the nonmetastatic variant AS showed adhesion and 
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spreading via vinculin-containing focal contacts. These cells also synthesize, 
secrete and assemble fibronectin at the pericellular area. The metastasizing 
ASML variant cells adhered to the substrate at a slower rate via thick 
cytoplasmic protrusions, but are removed from the substrate by trypsin-EDTA 
slower than the non-metastasizing AS variant cells. The ASML cells also 
synthesize very low levels of both vinculin and fibronectin, display a diffuse 
pattern of actin and tubulin organization, and are unable to spread on substrates. 
Spreading could not be induced in the ASML cells by seeding the cells on an 
extracellular matrix derived from bovine corneal endothelial cells or on 
concanavalin A (conA)-coated substrates, or by the addition of db-cAMP to the 
medium (Matzku et al., 1983; Raz et al., 1985). To further define differences 
between the two sublines, monoclonal antibodies were generated and selected 
for those that only bind to the metatastasizing ASML cells (Matzku et al., 1989). 
With the help of these monoclonal antibodies, the genes of suggestedly 
metastasis associated molecules were identified. One of these molecules is 
C4.4A. 
 
1.4. C4.4A: A metastasis-associated molecule 
C4.4A is a 65-100 kDa glycosylphosphatidylinositol (GPI)-anchored molecule, 
which shows 46.9% homology to uPAR (Rösel et al., 1998). It belongs to the 
Ly6/uPAR/alpha-neurotoxin (LU) protein domain family. The gene coding for 
human C4.4A is located on chromosome 19q13. It is composed of 4870 bp and 
5 exons. A putative role of C4.4A in cancer invasion and metastasis was 
emphasized by the finding that only metastasizing rat carcinoma expressed 
C4.4A (Claas et al., 1996; Rösel et al, 1998). Cloning of human C4.4A 
confirmed preferential expression in metastatic tissue (Würfel et al., 2001). 
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1.4.1. The C4.4A protein 
C4.4A consists of 346 amino acid residues, including a 30 residues signal 
peptide at the N-terminal and a C-terminal signal sequence for GPI anchorage 
(38 residues) that are cleaved post-translationally, yielding a mature protein of 
278 residues, anchored to the cell membrane via GPI. It contains two LU 
domains (domains I and II), each of about 90 amino acids, and a serine-, 
threonine-, proline-rich (STP-rich) region. LU domains adopt a "three-fingered" 
folding topology that is characterized by 4 consensus disulfide bonds and an 
invariant C-terminal asparagine. Intriguingly, domain I of C4.4A lacks one 
consensus cysteine bond, which is crucial to the proper folding of the single 
domain LU proteins (Jacobsen and Ploug, 2008). The STP-rich region is highly 
O-glycosylated, with 17 potential O-glycosylation sites. None of the 6 potential 
N-glycosylation sites of C4.4A are, however, located in this region (Rösel et al, 
1998; Jacobsen and Ploug, 2008). Different degrees of glycosylation can 
probably explain the large variation in molecular weight observed in C4.4A 
from different sources (Paret et al., 2007; Hansen et al., 2004), deviating from 




Figure 4: Protein structure of C4.4A. (A) Structural representation of the two LU domains and the 
STP-rich region of C4.4A (modified from Hansen et al., 2004). Insert: Ribbon diagram of the three-
finger fold of a single LU domain (made in PyMOL™(DeLano Scientific), using PDB coordinates 
1NEA). (B) Disulfide connectivity in C4.4A, with LU consensus cysteine bonds highlighted in yellow 
(Jacobsen and Ploug, 2008). 
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1.4.2. Expression of C4.4A  
Transcription of the C4.4A gene requires the contribution of the transcription 
factor C/EBPbeta. This transcription is strongly enhanced by JunD and c-Jun 
such that C4.4A is even transcribed in a C4.4A-negative tumor cell line after 
cotransfection with C/EBP plus JunD or c-Jun (Fries et al., 2007).  
Human and rat C4.4A have been demonstrated to be expressed in several types 
of carcinoma like mammary, renal cell, colorectal (Smith et al., 2001; Würfel et 
al., 2001; Seiter et al., 2001; Fletcher et al., 2003; Hansen et al. 2004; Paret et 
al., 2007) and most pronounced non-small cell lung cancer (Hansen et al., 
2007). Its expression in other types of cancer, like esophageal cancer and 
malignant melanoma becomes regulated during tumor progression (Seiter et al., 
2001; Hansen et al., 2008; Wang et al., 2006). C4.4A is not expressed on 
leukemia and lymphoma (Würfel et al., 2001). However, weak C4.4A 
expression already at the stage of hyperplasia suggests that C4.4A may also be 
an early biomarker for a possibly more malignant subtype of adenocarcinoma 
(Jacobsen et al., 2011).  
Besides on malignant tumors C4.4A expression has been observed in the rat 
only on basal to suprabasal layers of keratinocytes, squamous epithelia of the 
upper gastrointestinal tract, urothelium and in placental tissue. In the adult 
mouse, a very similar expression profile has been seen: suprabasal layers of the 
squamous epithelia of the oral cavity, esophagus, non-glandular portion of the 
rodent stomach, anus, vagina, cornea, and skin (Claas et al. 1996; Rösel et al., 
1998; Smith et al, 2001; Hansen et al., 2004; Kriegbaum et al., 2011). Though 
C4.4A is tethered to the cell membrane via a GPI-anchor, it can under certain 
conditions also be found intracellular. Tumor cell lines release C4.4A by vesicle 
shedding and proteolytic cleavage (Paret et al., 2007). A soluble fragment of 
C4.4A, termed C4.4A', resulting from cleavage in the protease-sensitive region 
between domain II and the STP-rich region, releasing the two N-terminal LU 
domains, has been described in esophageal tissue (Hansen et al., 2008).  
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1.4.3. Function of C4.4A  
Despite the structural homology of C4.4A to the urokinase receptor (uPAR), 
there is no evidence for shared functions. uPAR has a well-established role in 
regulating and focalizing uPA-mediated plasminogen activation to the surface of 
those cells expressing the receptor. Instead, the biological function of C4.4A 
remains elusive. Circumstantial evidence, nevertheless, points to a role of C4.4A 
in the modulation of cell-cell and/or cell-matrix interactions (Rösel et al, 1998; 
Paret et al., 2005; Hansen et al., 2008). Association of C4.4A with LN1 (also 
known as LN111) and LN5 (alternative name LN332), induces spreading, 
lamellipodia formation and migration. The carbohydrate-binding protein 
galectin-3, which has been reported to be involved in cell/cell interactions, cell 
adhesion, migration, invasion and metastasis, has also been identified as a ligand 
for C4.4A (Paret et al., 2005). C4.4A and the cell adhesion molecule E-cadherin 
are co-expressed in the normal esophageal mucosa, and both are down-regulated 
in the progression to dysplasia (Hansen et al., 2008). C4.4A-positive and not 
C4.4A-negative tumor cells are capable of penetrating a matrigel, and this 
process can be inhibited by a monoclonal anti-C4.4A antibody. Encapsulation of 
lung metastases in rats, arising after an intrafootpad injection with pancreatic 
tumor cells, disappears, when these tumor cells are transfected with C4.4A 
(Rösel et al., 1998). C4.4A has been reported to be a novel substrate for the 
extracellular matrix-degrading metalloproteases ADAM10 and ADAM17, 
which have been implicated in cell migration and proliferation, with a bearing 
on tumor invasion and metastasis (Esselens et al., 2008). 
Taken together, there is circumstantial evidence for C4.4A being engaged 
mostly in cell matrix interaction and possibly matrix degradation, without 
insight into the molecular mechanism. 
 21 
1.5 Aim of thesis 
C4.4A was first identified in a screening designed to select membrane proteins 
overexpressed in metastasis. Due to its very restricted expression in non-
transformed tissue and its well defined overexpression in several epithelial 
tumors, C4.4A offers itself as a diagnostic marker. Its potential use as a 
therapeutic target is hampered by the lack of knowledge about its functional 
activity. I approached this open question, by focusing on the previously reported 
connection between C4.4A upregulation in wounded tissue as well as in tumors 
in hypoxia. Central to my work were three questions: 
1. Does hypoxia regulate C4.4A transcription? 
It has been reported that C4.4A transcription requires CEBPβ and is supported 
by JunD and c-Jun. I focused on HIF1, one of the main transcription factors 
regulating hypoxia-induced genes. HIF1 could indeed be engaged in C4.4A 
transcription, as the C4.4A promoter contains 3 HIF responsive elements. 
2. Does hypoxia affect the interaction of C4.4A with the extracellular matrix? 
It has been established that C4.4A binds to laminins 1 and 5. It also is known 
that C4.4A transiently contributes to laminin adhesion, whereas it promotes 
motility on laminin for a long time. However, the underlying molecular 
mechanims are unknown. Based on the results of these studies, I wanted to 
confirm 
3. the in vivo relevance of C4.4A in the metastatic process. 
To approach this last question, I generated a C4.4A knockdown of the metastatic 
rat ASML tumor line, whose growth behavior and functional activities were 
compared in vivo and in vitro with that of the parental line. 
C4.4A responds to hypoxia, though not at the transcriptional level. It mostly acts 
as a molecular facilitator by recruiting the 64 integrin and by MMP14 
activation. Thereby cell bound, but also exosomal C4.4A promotes tumor cell 
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motility and invasiveness. Via the association with 64 it also becomes 
engaged in apoptosis resistance. 
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Agitator for bacterial cultures  Edmund Buehler GmbH, Hechingen  
ELISA Reader Thermo Scientific, Langenselbold 
Camera system Spot CCD  Diagnostic Instruments, Sterling Heights, USA  
Cell chamber Neubauer improved  Brand, Wertheim  
Centrifuge Sorvall RC5B Plus  Kendro, USA  
Centrifuge Biofuge fresco  Heraeus, Hanau, Hanau  
DNA-agarose gel electrophoresis chamber  Bio-Rad, Munich  
FACS Calibur  Becton-Dickinson, Heidelberg  
Fuji Film Imaging Plate BAS-MS 2325 Fuji Photo Film, Düsseldorf 
Hyper processor (for processing films)  Amersham, Freiburg  
Incubator for bacteria  Melag, Berlin  
Incubator for cell culture  Labotec, Goettingen  
Master cycler (PCR cycler)  Eppendorf, Hamburg,  
Magnetic stirrer 3000  Heidolph, Keilheim  
Microscope DMBRE  Leica, Bensheim  
Microwave  Phillips, Wiesbaden 
Phosphorimager Fuji Film BAS-1800II Fuji Photo Film, Düsseldorf 
Photocassette  Amersham, Freiburg  
Ph-Meter-761 Calimatic  Knick, Berlin  
Photometer Ultraspec III  Amersham, Freiburg  
Pipettus-Akku  Hirschmann, Eberstadt  
Pipettes  Eppendorf, Hamburg  
Power supply PS 9009  GIBCO, Darmstadt  
Rotor GSA  Kendro, USA  




Rotor SW41 Ti  Beckman Coulter, Krefeld  
Speedvac centrifuge Bahofer, Reutlingen 
Sterile hood  Heraeus, Hanau  
Sonicator Sonoplus  Bandelin, Berlin  
Table top centrifuge  Heraeus, Hanau  
Transfer apparatus Mini Trans-Blot®  Bio-Rad, Munich  
Thermo-mixer  Eppendorf, Hamburg  
Ultrasound homogenizer  Bandelin Electronik  
Water-bath  Julabo, Seelbach  
Weighing scale RC210 D  Sartorius, Goettingen  
Whirlmixer Vortex Genie  Si Inc., New York, USA  
 
2.1.2. Miscellanoeus materials 
Name Company 




  Greiner, Frickenhausen  
Cell culture 96-well, 24-well, 6-well plates  Greiner, Frickenhausen  
Centrifugal concentrators Vivaspin 6ml, 20ml  Vivascience, Hannover  
Cryovials  Greiner, Frickenhausen  
Coverglass  R. Langenbrinck, Emmendingen  
Dako pen  DakoCytomat., Glostrup, Denmark  
Electroporation cuvettes  Eugentec, Seraing, Belgium  
Falcon tubes 15ml, 50ml  Greiner, Frickenhausen  
Glass slides  R. Langenbrinck, Emmendingen  
Hyperfilm ECL Amersham, Freiburg 
Needles BD Biosciences, Heidelberg,  
Nitrocellulose membrane Hybond ECL  Amersham, Freiburg  
Parafilm  Greiner, Frickenhausen 
Petridishes  Greiner, Frickenhausen  
Pipette tips  Sarstedt, Numbrecht  
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Name Company 
Sterile filter 0.2μm  Renner, Darmstadt  
Syringes  BD Biosciences, Heidelberg  
Trans-well migration (Boyden) chambers 48 well  Neuroprobe, Gaithusberg, USA  
WhatmanTM 3MM paper  Scleicher & Schüll, Dassel  
2.1.3. Chemicals and reagents 
Name Company 
Acetic acid  Riedel-de Haen, Seelze  
Acetone 
Acetyl-CoA   
Fluka, Buchs, Switzerland  
Calbiochem, Bad Soden garose  Sigma, Steinheim  
Ammonium persulphate (APS)  GIBCO, Darmstadt  
Ampicillin sulphate  Calbiochem, Darmstadt  
Bactoagar  Fluka, Buchs, Switzerland  
Bio-Rad, Munich Bradford reagent  Bio-Rad, Munich  
Bovine Serum Albumin (BSA)  PAA, Pasching, Austria  
Bradford Sigma, Steinheim 
Brij 96  Fluka, Buchs, Switzerland  
Bromo phenol blue  Merck, Darmstadt  
Calcium chloride  Merck, Darmstadt  
Chloroform Riedel-de Haen, Seelze 
D-threo-Chloramphenicol- (dichloroacetyl-1-
14
C) Sigma, Steinheim 
Coomassie R-250  Merck, Darmstadt  
Crystal violet  Sigma, Steinheim  
Dimethyl formamide  Merck, Darmstadt  
Dimethyl sulfoxide (DMSO)  Merck, Darmstadt  
Ethanol  Riedel-de Haen, Seelze  
Ethidium bromide  Merck, Darmstadt  
Ethylenediamine tetraacitic acid (EDTA)  Sigma, Steinheim  
Foetal Calf Serum (FCS)  PAA, Pasching, Austria  
Formaldehyde (37%)  Merck, Darmstadt  
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Name Company 
G418 sulphate  PAA, Pasching, Austria  
Gelatine (cold water fish skin)  Merck, Darmstadt  
Glucose  Merck, Darmstadt  
L-Glutamine  AppliChem, Darmstadt  
Glycerine  Roth, Karlsruhe  
Glycine  GERBU, Gaiberg  
HEPES  GERBU, Gaiberg  
HiPerfect-Reagent for transfection  Quiagen, Hilden  
Hydrochloric acid (HCl)  Riedel-de Haen, Seelze  
Hygromycin  PAA, Pasching, Austria  
Immersion oil  Zeiss, Goettingen  
Isoves DMEM Medium Invitrogen, Darmstadt 
Lipofectamine Invitrogen, Darmstadt 
Magnesium carbonate  Merck, Darmstadt  
Magnesium chloride  Merck, Darmstadt  
Magnesium sulphate  Merck, Darmstadt  
Milk powder  Roth, Karlsruhe  
Methanol  Riedel-de Haen, Seelze  
N,N,N´N´-Tetramethylenediamine (TEMED)  Sigma, Steinheim  
Paraformaldehyde  Sigma, Steinheim  
Penicillin  Sigma, Steinheim  
Phenylmethylsulphonylfluoride (PMSF)  Sigma, Steinheim 
PMA Sigma, Munich 
Potassium acetate  Sigma, Steinheim  
Potassium carbonate  Roth, Karlsruhe  
Potassium chloride  Merck, Darmstadt  
Potassium dihydrogenphosphate  Merck, Darmstadt  
Potassium tetrathionate  Merck, Darmstadt  
Protease Inhibitor Cocktail Tablets  Roche Diagnostics, Mannheim  
Protein G Sepharose 4 Fast Flow  Amersham Biosciences, Freiburg  
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Name Company 
Puromycin Calbiochem, Darmstadt 
RPMI 1640  GIBCO, Darmstadt  
Sodium acetate  Merck, Darmstadt  
Sodium azide  AppliChem, Darmstadt  
Sodium carbonate  AppliChem, Darmstadt  
Sodium chloride  Fluka, Buchs, Switzerland  
Sodium hydrogen phosphate  Merck, Darmstadt  
Sodium dodecyl sulphate (SDS)  GERBU, Gaiberg  
Sodium hydrogen carbonate  AppliChem, Darmstadt  
Sodium hydroxide  Riedel-de Haen, Seelze  
Tris  Roth, Karlsruhe  
Tritic YG AppliChem, Darmstadt 
Triton-X-100, Triton-X-114  Sigma, Steinheim  
Trypan bue  Serva, Heidelberg  
Trypsin  Sigma, Steinheim  
Trypton  AppliChem, Darmstadt  
Tween 20  Serva, Heidelberg  
Yeast Extract  GIBCO, Darmstadt  
 
2.1.4 Buffers and solutions 
Bicarbonate buffer  15mM Na2CO3, 35mM NaHCO3, pH 9.6  
Blot buffer  25 mM Tris, 192mM Glycine, 0.1% SDS, 20% Methanol  
Ethidium Bromide  0.01% (w/v) in water. Store in dark.  
Freezing medium  10% DMSO in FCS  
HEPES buffer  25mM HEPES, 150 mM NaCl, 5mM MgCl2, 1 mM PMSF, 
Protease inhibitors  
6x Laemmli-buffer  350mM Tris, pH6.8, 10% (w/v) SDS, 36% (w/v) Glycerine, 
0.01% (w/v) Bromophenol blue  
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LB medium  10g peptone, 5g yeast extract, 10g NaCl. Make volume to 
1l. Add 15g agar for LB plates 
Running buffer (10X)  1%SDS (w/v), 144g Glycine, 30g Tris. Make volume to 1l 
with bidestilled water  
PBS  137 mM NaCl, 8.1mM Na2HPO4, 2.7 mM KCl, 1.5mM 
KH2PO4, pH 7.4 
RIPA buffer 25 ml Tris.HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS 
Stripping buffer  62.5 mM Tris-HCl (pH 6.8), 2% SDS ,0.1 M, 2-
Mercaptoethanol  
TAE buffer 242g Tris base, 57.1ml Glacial acetic acid, 100ml 0.5M 
EDTA pH 8.0. Make volume to 1l and adjust pH to 8.5 
TEN buffer 40mM Tris/Cl pH 7.5, 1 mM EDTA pH 8.0, 150 mMNaCl 
 
2.1.5 Enzymes  
Name Company 
Restriction enzymes  MBI Fermentas, St. Leon-Rot, Germany  
Taq polymerase  MBI Fermentas, St. Leon-Rot, Germany  
T4 Ligase  MBI Fermentas, St. Leon-Rot, Germany 
Calf Intestinal alkaline phosphatase (CIAP)  MBI Fermentas, St. Leon-Rot, Germany  
 
2.1.6 Kits  
Name Company 
Qiaquick gel extraction kit  QIAGEN, Hilden, Germany  
Qiaquick Midiprep kit  QIAGEN, Hilden, Germany  





GeneRulerTM 100bp  and 1Kb DNA-Ladder Plus  MBI Fermentas, St. Leon-Rot  
PagerulerTM Prestained Protein Ladder  MBI Fermentas, St. Leon-Rot  
 
2.1.8 Antibodies 
2.1.8.1 Primary antibodies 
Antibody Provider / Company 
C4.4 (anti-rat C4.4A) Matzku et al., 1989 
D5.7 (anti-rat EpCAM) Matzku et al., 1989 
B5.5 (anti-rat α6β4) Matzku et al., 1989 
anti-human C4.4A Paret et al., 2007 
anti-rat panCD44 (clone Ox50) European Association of Animal cell cultures, Porton 
Down, UK 
anti-rat uPAR American Diagnostica, Pfungstadt 
anti-rat uPA American Diagnostica, Pfungstadt 
anti-rat TACE Stressgen, Ann Arbor, MI, USA 
anti-rat MMP14 Santa Cruz Biotech, Heidelberg 
anti-rat HIF1α Santa Cruz Biotech, Heidelberg 
anti-rat β4 BD, Heidelberg 
anti-actin BD, Heidelberg 
anti-fibronectin BD, Heidelberg 
anti-rat LN1 BD, Heidelberg 
anti-human LN5 (crossr. rat) BD, Heidelberg 
rLS3 (anti-human LNα3 chain) Nakashima Y et al., 2005 
8A5212 (anti-hu.LNβ3 chain) Nakashima Y et al., 2005 
D4B5 (anti-human LN2 chain)  Nakashima Y et al., 2005 
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2.1.8.2 Secondary antibodies 
Antibody Company 
anti-mouse IgG-APC BD, Heidelberg, Germany 
anti-mouse IgG-HRP Dianova, Hamburg, Germany  
anti-mouse IgG-PE Dianova, Hamburg, Germany  
anti-rabbit IgG-HRP Dianova, Hamburg, Germany 
anti-hamster IgG Dianova, Hamburg, Germany   
Streptavidin-HRP Sigma, Steinheim, Germany  
 
2.1.9 Matrix proteins 
Protein Company 
Fibronectin (2µg/ml) Sigma, Munich, Germany 
LN1(5µg/ml) Sigma, Munich, Germany 
rat LN1 Sigma, Munich, Germany 
human LN5 A431 exosome-depleted culture supernatant w/o FCS 




Aprotinin (serine protease inhibitor) (10µM) Sigma, Munich, Germany  
MMP9/13-Inhibitor-II (MMP-Inh.II) (3µM) Merck, Darmstadt, Germany 
TAPI (TACE Inhibitor) (40µM) Merck, Darmstadt, Germany 
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2.1.11 Nucleic acids 




































HRE1: -674 bp: bold violet; HRE2: -1184 bp: bold green; HRE3: - 1558 bp: bold red; start 
codon: bold. 
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2.1.11.2. Primers for HRE mutating CGTG to CTGT 
HRE 1 for: 5´-CTTCTCAATTTCAGCTCGACTGTTAGCCCTTTATCCG-3´ 
HRE 2 for: 5´-ATGGGGTGGAGGGACCACTCTGTGTTTTATTACTCAAT-3´  
HRE 3 for: 5´-GTTCTGTCTTGGCCTCCTACTGTCTGAACTACAGGGA-3´ 
 
2.1.11.3. Other primers 
C4.4A for: 5´-CTACAGCTG CGTGCAAAAGG-3´ 
C4.4A rev: 5´-GTTGAGTTTGGCGTTGCAT-3´ 
β-actin for: 5´-TCATGAAGTGTGACGTTGACATCCGT-3´ 
β-actin rev: 5´-CCTAGAAGCATTTGCGGTGCACGATG-3´ 
 
2.1.11.4. Sequence of siRNA targeting C4.4A 
Sequence Provider 
C4.4A rat, SI02011919 QIAGEN, Hilden  




pEGFP-C1 Plasmid (Clontech, Palo Alto) 
pcDNA3.1/CAT (Invitrogen, San Diego) 
pBLCAT3 und pBLCAT2 (Luckow and Schütz, 1987) 
pSUPERneo+gfp (Oligoengine, Seattle, USA) 
p(HA)HIF1α (401Δ603) (Huang et al., 1998) 
p(HA)HIF1α (Huang et al., 1998) 
 
2.1.12 Bacterial strain 
E.coli DH5α  Genotype: F-, Φ80dlacZΔM15, Δ(lacZYA-
argF)U169, deoR, recA1, endA1, hsdR17(rk-
,mk+), phoA, supE44, thi-1, gyrA96, rel A1, λ- 
(Invitrogen, Darmstadt, Karlsruhe)  
E.coli oneShot®TOP10  F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(araleu)  
7697 galU galK rpsL (StrR) endA1 nupG 
(Invitrogen, Darmstadt)  
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2.1.13 Computer software  
Promoter analysis: Alibaba 2.1: Phttp://darwin.nmsu.edu/~molb470/fall2003/ 
Projects/solorz/aliBaba_2_1.htm: Promoter analysis 
Primer design: IDT
®
: http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer  
Nucleotides downloading: http://www.ncbi.nlm.nih.gov/nuccore/NM_021759  
FACS analysis: Cell Quest analysis program  
Fluorescence analysis: SPOT2.1.2  
Signal quantification: ImageJ 
Nucleotides alignment: Gentle  
 
2.1.14 Tumor lines 
BSp73ASML (C4.4A
+
) metastasizing rat pancreatic adenocarcinoma line 
(Matzku et al., 1983)  
BSp73AS (C4.4A
-
) non-metastasizing rat pancreatic adenocarcinoma 
line (Matzku et. al, 1983)  
BSp73AS1B (C4.4A
+




) rat colon carcinoma line (Martin et al., 1983) 
804G rat bladder carcinoma line, LN5 secreting (Homma et 
al., 1985)  
Human A431 human epidermoid line, LN5 secreting 
(Panneerselvam et al., 1985) 
Capan2 human pancreatic adenocarcinoma line, 
metastasizing (Takomori et al., 1996) 
Colo357 human pancreatic adenocarcinoma line, 
metastasizing (Morgan et al., 1980) 
8.18 human pancreatic adenocarcinoma line, weakly 
metastasizing (personal observation) (Tumor Bank, 
German Cancer Research Center, Heidelberg) 
BxPC3 human pancreatic adenocarcinoma line non-
metastasizing (Tan et al., 1996)  
 34 
2.1.15 Rat strain 
For experiments 8-12 weeks old BDX rats were used. The rats were bred in the 
animal facility of the University of Heidelberg under pathogen-free conditions 
and were provided sterile food and water ad libitum.  
 
2.2 Methods  
2.2.1 Molecular biology 
2.2.1.1 Cloning 
2.2.1.1.1 Dephosphorylation  
The formation of a phosphodiester bond between adjacent nucleotides can be 
repressed by removing the 5' phosphates from both ends of the linear DNA with 
calf intestinal phosphatase (CIAP, MBI Fermentas). 1-5 µg of digested DNA 
were mixed with 1 µl of CIAP (5U) and incubated at 37°C for 1 hour. The 
reaction product was used for ligation. 
 
2.2.1.1.2 Ligation 
Joining linear DNA fragments together with covalent bonds is called ligation. 
Briefly, 1-5 µg of digested and dephosphorylated plasmid DNA were mixed 
with the insert (to a ratio depending on the amount of both DNA), the T4 DNA 
ligase and the ligase buffer. The mixture was incubated at 16°C overnight. 
Ligation products were used for bacteria transformation.  
 
2.2.1.2 Competent bacteria 
Competent bacteria are adapted to receive heterogeneous DNA with high 
efficiency. For experiments, competent bacteria were made chemically. 1ml 
from bacteria overnight culture was added to 100 ml Luria Bertani (LB) medium 
without antibiotic and grew till the O.D.600nm reaches 0.5 – 0.6. Cells were 
spun down in the Sorvall GSA rotor at 5,000 RPM for 5 min at 4
o
C and bacteria 
pellet was gently resuspended in 15 ml of filtered transforming buffer I. After 10 
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min incubation on ice, cells were again spun at 4,000 rpm in the Sorvall GSA 
rotor for 10 min and the bacterial pellet was resuspended in 2 ml of ice cold 
transforming buffer II. 100 µl of bacteria were aliquoted in 1.5 ml Eppendorf 




2.2.1.3 Transformation  
In molecular biology, the transformation is the introduction of a foreign plasmid 
into competent bacteria to amplify the plasmid. 50 µl of competent bacteria were 
unfrozen on ice, 0.1 – 1 µg of plasmid was added and kept on ice for 30 min. 
Then, the cells were heated (heat shock) at 42°C for 45 – 60 seconds and kept on 
ice for 2 min. 200 µl SOC medium without antibiotics were added and kept on 
the shaker at 250 rpm for 1hour at 37°C. 10 – 50 µl of the broth were plated on 
LB agar plate containing selection drug (ampicilline at 100µg/ml). Plates were 
incubated overnight at 37°C to get colonies.   
 
2.2.1.4 DNA extraction 
2.2.1.4.1Miniprep 
Single colonies were picked from LB agar plate and put in 3 ml LB medium 
containing antibiotic, and shaked at 250 rpm at 37°C overnight. 1.5 ml of 
bacterial culture was used for mini-prep according to the supplier´s 
recommendations (Miniprep kit, Qiagen). Positive clones were checked on 
agarose gel with ethidium bromide staining after enzymatic digestion and 
cultivated at 37°C overnight with shaking for midi-preparation. 
 
2.2.1.4.2 Midiprep  
Midiprep System is designed to isolate high-quality and large amount of plasmid 
DNA for use in eukaryotic transfection. Overnight culture of positive clones was 
used for midiprep according to the supplier´s recommendations (Midiprep kit, 
Qiagen).  
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2.2.1.5 RNA isolation 
For total RNA extraction, 8 x 10
6 
cells were mixed with 1 ml reagent Tritic YG 
and incubated at room temperature (RT) for 10 min. Then, 200 µl of chloroform 
was added and vigourously vortexed for 2- 15 min at RT. After 15 min 
centrifugation at 12000 RPM at 4°C, the upper aqueous layer was collected and 
mixed with 500 µl isopropanol. The mixture was centrifuged at 12000 RPM for 
10 min at 4°C. The pellet was washed two times with chilled  70% ethanol at 
12000 RPM for 5 min at 4°C. Finally, the pellet was dried, re-suspended in 25 
ml sterile water and store at -80°C. 
 
2.2.2 Cell biology  
2.2.2.1 Cell culture  
Tumor cells were cultured in an incubator at 37°C, 5% CO2, 95% humidity. 
Cells were maintained in RPMI 1640- or Iscove´s medium, containing 10% heat 
inactivated fetal calf serum (FCS), 100U/ml penicillin, 100μg/ml streptomycin. 
Where indicated, cells were cultured in the presence of 200µM CoCl2 for 12h, to 
mimic hypoxic conditions. Confluent cells were detached with trypsin, EDTA or 
pippeting up and down. The cells were split at a ratio of 1 : 4. Long term cell 
storage was done by washing the cells once with fresh medium, resuspending 
the cells in ice-cold FCS/10% DMSO, keeping the cells in vials overnight at -
80°C and transferring the vials into liquid nitrogen.  
To unfreeze cells from liquid nitrogen, vials were kept in the water bath at 37°C, 
till a little bit of ice remains, and immediately transferred into 15 ml Falcon 
tubes containing fresh medium. The cells were centrifuged at 1600 rpm for 4 
min. The supernatant was removed and the cells resuspended in fresh medium 
and transferred into new flask. The cell viability was assessed under the light 
microscope by trypan blue staining.   
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2.2.2.2 Transfection of tumor lines 
The introduction of nucleic acids into eukaryotic cells by nonviral methods is 
defined as transfection. Briefly, 12 hours before transfection, 4 x 10
5
 ASML 
cells were seeded in a 6 well-plate. At 70-80% confluency, cells were 
transfected with 3µg pBLCAT3-C4.4A, 1µg EGFP-C1 or 1.75µg pBLCAT3-
C4.4A, 1.25µg p(HA) HIF1α 401∆603 (HIF-1α with oxygen-dependent 
degradation domain deletion), 1µg EGFP-C1 using Lipofectamine
TM
 2000 
according to the supplier´s recommendations. 
To generate a stable C4.4A knock down line, 48 hours after transfection, C4.4A 
siRNA transfected cells were put under selection pressure with neomycin. 
Transfected cells were selected by cloning under limiting dilution with 1 or 3 
cells/well in 96 well-plates. The cells were checked by FACS after each 
recloning step until uniformly positive clones were obtained. 
 
2.2.2.3 Chloramphenicol acetyl transferase (CAT) assay 
After transfection with the C4.4A promoter constructs and pEGFP-C1 as 
described above, cells were washed two times with PBS. After 5 min incubation 
(4
o
C, 1 ml TEN buffer), cells were scrapped, transferred to Eppendorf tubes and 
centrifuged (5 min, 5000 rpm). Cells were resuspended in 80 µl ice cold Tris/Cl, 
and lysed by freezing / thawing. Lysates (900 µl) were centrifuged at full speed 
for 5 min. The supernatant was transferred into Eppendorf tubes. After 
determining the protein content by Bradford, samples were kept at -80°C. 
To normalize the CAT extracts, remaining 100 µl of cell suspension were used 
to determine via FACS the transfection efficiency based on GFP expression. 
Using the protein concentration and the transfection efficiency, the volume of 
protein for the CAT reaction was determined as followed: Volume = 10% x µl 
volume of lysate (containing 100µg)/transfection efficiency. The CAT reaction 
was prepared by mixing: 2 µl 
14
C labeled Chloramphenicol, 20 µl 4 mM Acetyl 
CoA (dissolved in 0.25 M Tris), x µl 0.25 M Tris/Cl, pH7.5, x µl cytoplasmic 
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cell extract, for a total volume of 150 µl. The mixture was incubated at 37 °C for 
3 h. Eight hundred µl of ethylacetate was added, then vortexed. After 
centrifugation (13000 rpm, 4°C, 5 min), the supernatant was transferred to 
Eppendorf tubes and evaporated in a Speedvac. The chloramphenicol pellet was 
resuspended in 12 µl ethyl acetate for thin layer chromatography (TLC). Prior to 
loading the TLC sheet with 
14
C chloramphenicol-ethylacetate, the TLC chamber 
was equilibrated with 150 ml mixture chloroform/methanol (19:1 v/v) and 2 
pieces of Whatmann paper. The probes were separated for 45 min. The dried 
TLC sheet was exposed to x-ray film for 12 h. The spots were quantified using 
the Phosphor Imager System. 
 
2.2.2.4 Adhesion assay 
Adhesion of cells treated with or without CoCl2 to BSA- and LN5-coated 96-
well plates was determined after 30 min and 240 min at 37
o
C. Non-adherent 
cells were removed by washing. Adherent cells were fixed with ice cold 
methanol and stained with 0.1% crystal-violet for 10 min. After washing with 
distilled water, drying and dissolving in 10% acetic acid, the OD at 595 nm was 
measured.  
 
2.2.2.5 Migration assay 
Migration was evaluated in Boyden chambers seeding cells in the upper 
chamber (RPMI/1%BSA) with/without CoCl2 and/or protease inhibitors. The 
lower chamber separated by an 8µm pore size polycarbonate-membrane, 
contained RPMI/1%BSA or 804G supernatant. Migrated cells on the lower 
surface of the membrane were fixed with ice cold methanol and stained with 
0.1% crystal-violet for 10 min. After washing with distilled water, drying and 
dissolving in 10% acetic acid, the OD at 595 nm was measured.  
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For in vitro wound healing, a subconfluent monolayer was scratched with a 
pipette tip. Wound closure, followed after 0h-72h by light microscopy, is 
presented as percentage of reduction of the freshly wounded area.  
 
2.2.2.6 Apoptosis assay  
To distinguish between necrotic and apoptotic cells, the AnnexinV-APC and 
propidium iodide (PI) (R & D systems, Wiesbaden-Nordenstadt, Germany) 
double staining was used. DNA fragmentation and the alteration of the 
permeability and phospholipid composition of the plasma membrane are the two 
main events of the apoptotic process. During apoptosis, phosphatidylserine 
translocates from the cytoplasmic side of the membrane to the extracellular side, 
and can be detected with AnnexinV. Propidium iodide (PI) dye is known to bind 
to the DNA of leaky cells. These features are exploited in apoptosis assay. Early 
apoptotic cells bind only to annexin V, late apoptotic cells bind to annexin V 
and Propidium iodide and necrotic cells bind to Propidium iodide. Cells were 
seeded in 96 well plate and treated with or without cis-platin, in the presence or 
absence of 200µM CoCl2. After 24h, 48h and 72h incubation, the cells were 
washed twice with the binding buffer by centrifugation (1600 rpm, 4 min) and 
stained with a mixture of AnnexinV-APC – PI for 15min in the dark at room 
temperature. The apoptotic status of cells was assessed by FACS. 
 
2.2.2.7 Soft agar assay 
Tumor cells in 0.3% agar were seeded on a preformed 1% agar layer and kept in 
the incubator. Where indicated, the cells were treated with 0.5 or 1µg/ml 
cisplatin. After 3 weeks, the colonies were counted and the pictures taken.  
 
2.2.2.8 Immunofluorescence 
Cells seeded overnight on BSA-, LN1-, LN5- or FN-coated cover slides were 




fluorochrome-conjugated secondary antibody (60min, 4
o
C), blocked, incubated 
with a second, dye-labeled primary antibody (60min, 4
o
C) and washed. Where 
indicated, cells were removed by EDTA. Cover slides were mounted in Elvanol. 
Shock frozen skin sections (7µm) were exposed to primary antibody, 
biotinylated secondary antibody and alkaline phosphatase-conjugated avidin-
biotin complex solutions. Sections were counter stained with H&E. Digitized 
images were generated using a Leica DMRBE microscope, a SPOT CCD 
camera and Software SPOT2.1.2. 
 
2.2.2.9 Flow cytometry 
The flow cytometry is a technique used to measure , besides other fluorescence 
labelling of individual cells. Briefly, 1-3 10
5
 cells detached with EDTA, were 
transferred to round bottomed 96 well plates. Cells were washed twice with 
FACS washing buffer (1xPBS, 1% FCS, pH7.4) and incubated with 40µl of the 
primary antibody (1-5μg/ml) for 30min at 4˚C. Then, cells were washed again 
twice, and incubated with 40µl of the secondary, fluorochrome-conjugated 
antibody (0.3-0.5μg/ml) for 30min at 4˚C in the dark. For intracellular staining, 
cells were fixed in 1% formalin (20min, 4˚C), washed and permeabilized with 
0.2% Tween in FACS washing buffer before incubation with the primary and 
secondary antibodies.  
For CAT assay standardization, cells were co-transfected with the EGFP-C1 
plasmid to evaluate transfection efficacy through EGFP expression.  
Cells were analyzed in a FACScan using the Cell Quest analysis program (BD, 
Heidelberg, Germany). 
 
2.2.2.10 Vesicle depletion and exosome preparation  
Cells were cultured for 48h in serum-free medium. Cells were treated with or 
without 200 µM CoCl2 for 12 hours. Supernatants were cleared by stepwise 
centrifugation (2x10min, 500g, 1x20min, 2000g, 1x30min, 10000g), then, 
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followed by 2.5h of ultracentrifugation at 100,000g using SW41Ti rotor in 
Beckman Coulter ultracentrifuge. The exosomes are recovered in the pellets, 
which were re-suspended in 1x PBS and the concentration measured by 
Bradford assay. The resuspended exosomes were stored at -80˚C. 
 
2.2.3 Protein Biochemistry  
2.2.3.1 Biotinylation  
Biotinylation is the process of attaching biotin to proteins and other 
macromolecules. The biotin-avidin/-streptavidin interaction is commonly 
exploited to detect and/or purify proteins because of the high affinity between 
these molecules. Briefly, cells were washed in cold HEPES buffer without 
detergent at 1600 RPM for 4 min at 4°C. After washing, cells were incubated 
with 0.1mg/ml biotin-X-NHS in HEPES buffer for 30 min at 4°C with shaking. 
Cells were quenched with PBS-200mM Glycine and lysed in HEPES buffer 
(containing 1% Brij96, 1mM PMSF and 1x protease inhibitor cocktail) for 
60min at 4°C. Exosomes biotinylation followed the same procedure as above, 
after quenching and washing, exosomes were pelleted by ultracentrifugation at 
100,000g for 2,5h. 
 
2.2.3.2 Immunoprecipitation (IP)  
Cells were lysed in HEPES buffer (containing 1% Brij96, protease inhibitor 
cocktail) for 60min at 4°C with shaking and centrifuged at 13,000 rpm for 10 
min at 4°C. 1 mg of cell lysates or 100 µg of exosomal lysates were incubated 
with antibody (2µg/ml or 200µl hybridoma supernatant) overnight and 
precipitated with 5% ProteinG Sepharose for 1h at 4°C. Washed complexes 
were dissolved in Laemmli buffer, boiled at 95°C for 5min and centrifuged 
shortly to separate sepharose beads from proteins. Proteins were separated on 
10% SDS-PAGE and transferred to nitrocellulose membranes (30V, 12h, 4°C). 
Membranes were blocked, blotted with primary and HRP-conjugated secondary 
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antibodies (1h, RT) and developed with the ECL kit or were stained with 
Coomassie blue. 
 
2.2.3.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique used to separate proteins according to size. The SDS is a detergent 
that can dissolve hydrophobic molecules but also has a negative charge attached 
to it. The PAGE allows different sized proteins to move at different rates. Two 
gels were used to separate proteins. At the top, the stacking gel (375mM Tris 
pH6.8, 0.1%SDS, 4% acrylamide-bisacrylamide, 0.1%TEMED (v/v), 0.1% 
(w/v) ammonium persulphate) concentrates proteins and allows them to enter 
the resolving gel at the same time. At the bottom, the resolving gel (375mM Tris 
pH8.8, 0.1%SDS, 10-12% acrylamide-bisacrylamide, 0.1%TEMED (v/v), 0.1% 
(w/v) ammonium persulphate) allows the separation of proteins. Once the gel 
has completely polymerized, boiled samples, under non-reduced or reduced 
conditions (with beta-mercaptoethanol) were loaded and the gel was run in 
running buffer at 60 volts. After electrophoresis, gels were either subjected to 
coomassie blue staining or western blot. 
 
2.2.3.4 Western blotting 
Western blot allows the detection of specific protein and the measurement of 
relative amounts of the protein present in different samples. The proteins were 
transfered to nitrocellulose membranes using pre-wet materials sacked as 
followed: case (clear side), sponge, Whatman paper, membrane, gel, Whatman 
paper, sponge and case (black side). This set was placed in the transfer apparatus 
with black side facing black. The transfer was performed at 30V, overnight, at 
4°C. The transfer was quickly checked by staining the membrane with 1x 
Ponceau S for a minute and destaining with distilled water. The membrane was 
blocked for 1 hour in 10 ml 1x PBS + 5% non-fat dry milk + 0.1%Tween 20 
(PBST), with shaking. The blocking is followed by blotting with the primary 
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antibody, overnight at 4°C on a shaking platform. After three times washing 
with 1x PBS + 0.1%Tween 20, the membrane was probed with horse radish 
peroxidase (HRP)-conjugated secondary antibody (diluted 1:10000 in PBST) for 
1h at room temperature, then, washed three times. For biotinylated proteins, the 
membrane was incubated with Streptavidin-peroxidase. Enhanced 
Chemiluminescence system (ECL, Amersham Biosciences) and X-ray film 
(Amersham Biosciences) were used to detect the proteins. 
 
2.2.3.5 Coomassie staining 
After electrophoresis, the gel was covered with the coomassie brilliant blue 
solution for 30 min on a shaker. After staining, the gel was destained with the 
coomassie destaining solution (50% (v/v) methanol and 10% (v/v) acetic acid in 
distilled water) until the protein bands were clearly visible.  
 
2.2.4 Animal experiments 
A 1cm diameter full thickness skin area was excised from the shaved back of 8 
weeks old BDX rats. At the time of excision, after 4days and 7days, rats 
received 100µg control IgG or C4.4 in 100µl PBS, perilesionally. Sterile gauze 
covering the wound was fixed with a whole body bandage. A 2cm diameter 
area, including the wound, excised immediately, after 1day, 4days, 7days and 





intrafootpad (ifp) or intraperitoneally (ip). PBS or cisplatin (1µg/g body weight) 
were given ip after 2d and 23d. Rats were controlled weekly for local, draining 
lymph node or intraperitoneal tumor growth, ascites, short breathing or weight 
loss. Animals were sacrificed when the draining lymph node (LN) reached a 
mean diameter of 2cm, ascites became obvious, rats became pale, fatigue, lost 




2.2.5 Statistical analysis 
For all assays, values represent the mean (±SD) of triplicates and/or 3 
repetitions. P-values (Student‟s t-test, in vitro assay, in vivo Kruskal-Wallis 
assay) <0.05 were considered statistically significant.  
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3. RESULTS 
C4.4A has been described as a metastasis associated molecule that also is 
involved in wound repair. Its function remains elusive. As tumor progression 
and wound repair are frequently associated with a state of hypoxia, I aimed to 
explore whether expression and/or functional activity of C4.4A are regulated by 
hypoxia. I started with exploring the question whether C4.4A transcription is 
regulated by hypoxia. It has been previously described by Fries and coworkers 
(2007) that transcription of C4.4A requires the transcription factor C/EBPβ. 
Moreover, transcription is further increased in the presence of Jun-D and c-Jun. 
Furthermore, uPAR, a structural homolog of C4.4A also was reported to become 
regulated under oxygen stress. Finally, the C4.4A promoter contains some 
putative HIF responsive elements (HRE). Thus, hypoxia might well regulate 
C4.4A expression. 
 
3.1 Hypoxia-induced C4.4A up-regulation 
To evaluate the impact of hypoxia on C4.4A expression, ASML and Prog (two 
metastatic C4.4A
+
 rat tumor lines), AS1B1 cells (C4.4A cDNA transfected AS 
cells) (Matzku et al., 1983; Rösel et al., 1998) and human pancreatic tumor lines 
(Colo357, 8.18, Capan2, BxPC3) were used.  
Cells were cultured in the presence of CoCl2, to mimic hypoxic conditions 
(Maytin et al., 1999). High C4.4A expression in ASML and Prog cells was 
increased already after 6h 200µM CoCl2-treatment and increased further during 
a 12h culture period. AS1B1 cells showed a minor increase only after 12h of 
culture in the presence of CoCl2. AS cells remained C4.4A
-
 (Fig.5A and 5B). 
Two human pancreatic cancer cell lines, Colo357 and Capan2, which express 
C4.4A at a medium to low level, responded to CoCl2-treatment with a dose- and 
time-dependent increase in C4.4A expression, where a subfraction showed very 
high expression after 200µM CoCl2-treatment. 8.18 cells, which do not express 
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C4.4A revealed very weak expression in about 15% of cells after 12h 200µM 
CoCl2-treatment. BxPC3 cells remained C4.4A
-
 (Fig.5C and 5D). 
 
Figure 5: Hypoxia-induced C4.4 up-regulation. (A,B) ASML, Prog and AS1B1 cells and (C,D) the 
human pancreatic cancer lines Capan2, Colo357, BxPC3 and 8.18 were cultured in the presence of ti-
trated amounts of CoCl2 for 6h-24h. (A,C) Expression of C4.4A was evaluated by flow cytometry. 
Representative examples and (A) mean values of intensity of C4.4A expression or (C) the mean per-
centage of stained cells in 3 different experiments is shown. CD44 expression served as control. Sig-
nificant differences due to CoCl2-treatment: *. (B,D) Lysates of untreated and CoCl2-treated cells were 
separated by SDS-PAGE, transferred and blotted with anti-C4.4A. Actin served as control.   
As shown by Western Blot and Flow Cytometry, C4.4A expression increases 
under hypoxia in rat (ASML, Prog and AS1B1) and human (Capan2, Colo357, 
BxPC3 and 8.18) tumor lines. C4.4A expression is not or very weakly induced 
by hypoxia in cell lines that do not express C4.4A in normoxia. Thus, hypoxia 
 47 
contributes to C4.4A up-regulation, but may not suffice to induce C4.4A 
transcription. 
 
3.2 C4.4A transcription is not promoted by HIF1α 
Under hypoxic conditions, HIF1α is stabilized and accumulates. Thus, it 
translocates into the nucleus and interacts with some co-activators, such as 
P300/CBP, to drive the expression of target genes. Under normoxic conditions, 
HIF1α is subjected to proteosomal degradation. AS, AS1B1 and ASML cells 
express HIF1α at low level under normoxia. In ASML cells, HIF1α showed a 
strong, dose-dependent increase after 12h CoCl2-treatment. Up-regulation was 
weak after 6h and declined beyond 12h. An increase in HIF1α was also seen in 
CoCl2-treated Capan2 and BxPC3 cells. As the latter do not express C4.4A after 
CoCl2-treatment, this finding suggests HIF1α by itself to be insufficient to 
induce C4.4A transcription (Fig.6). 
 
Figure 6: HIF1α expression. ASML, Capan2 and BxPC3 cells were cultured in the presence of 
200µM CoCl2 for 6h-24h. HIF1α expression was evaluated by WB, actin served as control.  
To study the C4.4A promoter activity, I performed the Chloramphenicol Acetyl 
Transferase (CAT) assay. CAT is a bacterial enzyme which inactivates 
chloramphenicol by acetylating it. In eukaryotic cells, there is no background 
CAT activity. Thus, the CAT assay is suitable to examine the promoter activity 
in the rat pancreatic adenocarcinoma line. The C4.4A promoter contains 3HRE 
at -674 bp, -1184 bp and -1558 bp (see 2.1.11.1) and we controlled whether 
HIF1α acts as a co-transcription factor in hypoxia. The C4.4A promoter from -
588 or from -1957 to -1bp were inserted into promoterless pBLCAT3 vector. 
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After transfection of ASML cells with C4.4A promoter constructs, promoterless 
pBLCAT3 vector (negative control), pcDNA3.1/CAT (positive control) and 
pEGFP-C1 for standardization, transfected cells were treated with 200µM CoCl2 
for 12 h. Then, cells were lysed and lysates were used for the CAT reaction. 
Finally, probes were subjected to thin layer chromatography (TLC) and 
developed using the affinity of 
14
C-labeled chloramphenicol. The CAT activity 
quantified by the Phosphor Imager System showed no significant changes 
(Fig.7A, 7B). Furthermore, to ensure that HIF1 does not directly influence the 
promoter activity, I mutated the 3 HRE using the primers listed in 2.1.11.2. 
After confirmation of the right mutation by sequencing, ASML cells were 
transfected with the 3 mutated HRE. Once more, we observed that the CAT 
activity remained unaltered in normoxia or hypoxia (Fig.7C) and only a slight 
increase in CAT activity was observed upon co-transfection with pCDNA3-
HIF1α, irrespective of HRE mutations (Fig.7D). 
The observation that the CAT activity does not vary when cells were transfected 
with non mutated or mutated constructs, or cotransfected with HIF1α expressing 
vector, led us to emphasize that hypoxia-induced C4.4A up-regulation does, at 




Figure 7: HIF1 does not promote C4.4A transcription. (A-D) The -1 to -1957bp C4.4A promoter 
region with/without the 3 HRE mutations and the -1 to -588bp sequence (no HRE) were cloned into 
the pBLCAT3 vector. The pcDNA3.1CAT vector (CMV promoter) served as positive, the 
promoterless pBLCAT3 vector as negative control. ASML cells were co-transfected with the EGFP-
C1 plasmid for standardization. Cells were cultured in the presence or absence of 200µM CoCl2 for 
12h. (A,B) Impact of CoCl2; (C) impact of the 3 HRE (mutated); (D) impact of HIF1α as revealed by 
co-transfection. (A-D) CAT activity was quantified using a PhosphorImager system. Relative CAT 
activity (mean±SD of 3 experiments) is shown. No significant differences have been seen. 
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Up-regulated C4.4A expression under hypoxia apparently does not rely on 
HIF1α -induced C4.4A transcription. Nonetheless, hypoxia promoted C4.4A up-
regulation. To exclude an only in vitro phenomenon, I next evaluated C4.4A 
expression in wound repair. 
 
3.3 Hypoxia-induced C4.4A up-regulation in wound repair 
Keratinocytes express C4.4A and several studies report that C4.4A might be 
engaged in wound repair (Jacobsen et al., 2008; Hansen et al., 2004; Paret et al., 
2005). To control these suggestions, I evaluated C4.4A expression after skin 
wounding. To obtain hints towards a functional involvement of C4.4A, rats were 
concomitantly treated with the C4.4A-specific antibody C4.4. Controlling for 
C4.4A expression and the impact of C4.4 on wound repair after full thickness 
skin excision, revealed striking C4.4A up-regulation at the leading front of 




Figure 8: Keratinocyte migration during wound healing and C4.4A expression. The back skin of 
BDX rats was wounded by a 1cm diameter full thickness skin excision. Rats received at day 0, 4 and 7 
after wounding a perilesional injection of 100µg control IgG or C4.4. At the time of wounding, after 1, 
4, 7 and 10 days a 2 cm area around the wound was excised and shock frozen. Slices (7µm) were 
stained with C4.4 or mouse IgG1 (control) and Mayer's hematoxilin (Scale bar: 100µm). Arrows 
indicate the migration front of keratinocytes. 
These findings confirmed upregulated C4.4A expression in hypoxia and, 
importantly, provided evidence for a functional contribution of C4.4A, as a 
blocking antibody significantly affects cell migration on the extracellular matrix. 
 
3.4 The engagement of C4.4A in matrix adhesion and migration 
The basal lamina is rich in LN5 and C4.4A is a receptor for LN1 and LN5. 
Thus, I questioned whether the engagement of C4.4A in wound repair may be 
due to the interaction between C4.4A and LN5. Adhesion to BSA- or LN5-

















) cells, which all adhered better to 
LN5 than BSA. In addition, after 30min, significantly more CoCl2-treated than 
untreated ASML, Prog and AS1B1, but not AS cells adhered to LN5 (Fig.9A). 
As the increase in binding was more pronounced in ASML and Prog, which both 
and distinct to AS, express α6β4, we next asked for the contribution of C4.4A 
versus α6β4 (Rabinovitz et al., 1996) to LN5 adhesion. Adhesion of ASML and 
Prog were both inhibited by B5.5 and C4.4, whereas binding of AS1B1 cells 
was only inhibited by C4.4. Notably, inhibition by both antibodies was stronger 
in CoCl2-treated Prog cells (Fig.9B). This was a first indication that under 




Figure 9: The impact of hypoxia and up-regulated C4.4A expression on LN5 adhesion. (A, B) 
Untreated and CoCl2-treated ASML, Prog, AS and AS1B1 cells were seeded on BSA- or LN5 
(LN332)-coated plates and cultured for 30min in the presence or absence of CoCl2. (B) Cultures 
contained, in addition, C4.4 or B5.5 (10µg/ml). (A, B) The percentage of adherent cells (mean±SD of 
triplicates) is shown. (A) Significant differences between BSA and LN5: *; significant difference of 
untreated versus CoCl2-treated cells: s. (B) Significant antibody inhibition: *.  
To control whether this cooperativity between C4.4A and α6β4 is supported by 
proximity or a direct association between C4.4A and α6β4, I first searched for 
co-localization. C4.4A and α6β4 did not co-localize in ASML and hardly in 
Prog cells, when seeded on BSA-coated plates. Some co-localization was seen 
in the presence of CoCl2 or on LN5-coated plates. Instead, C4.4A and α6β4 
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Figure 10: Co-localization of C4.4A with α6β4 under hypoxia. (A) ASML and Prog cells were 
cultured on LN5 (LN332)-coated cover slides in the absence or presence of CoCl2. Fixed cells were 
stained with B5.5 / anti-mouse IgG-Cy2 (g) and, after blocking, with C4.4-TxR (r). Single 
fluorescence staining and digital overlays are shown (Scale bar: 10µm). (B) ASML cells were cultured 
for 16h in the presence or absence of CoCl2. Lysates were immunoprecipitated with B5.5. After SDS-
PAGE and protein transfer, membranes were blotted with C4.4 and anti-β4. 
Notably, hypoxia not only strengthened co-localization, but also supported a 
direct association between the two molecules as the amount of C4.4A co-
immunoprecipitating with α6β4 was close to 10-fold increased (Fig.10B). 
Taken together, hypoxia increases LN5 adhesion, which is equally well inhibited 
by C4.4 and B5.5 indicating that LN5 adhesion might pursue by a C4.4A-α6β4 
complex, which has been confirmed by co-localization and co-im-
munoprecipitation of the two molecules. 
We had reported that C4.4A-mediated LN5 binding is transient and could be 
restored in the presence of a protease inhibitor (Rösel et al., 1998). This also 
accounts for CoCl2-treated cells. After 4h, adhesion to LN5 did not consistently 
exceed adhesion to BSA and the adhesion supporting effect of CoCl2-treatment 
was weak or abolished. Adhesion of CoCl2-treated cells was partly restored in 
the presence of a broad serine protease inhibitor (aprotinin) and, more 
efficiently, a broad MMP inhibitor (MMP-Inh.II) (Fig.11). 
 
Figure 11: The impact of protease inhibitors on LN5 adhesion: Untreated and CoCl2-treated 
ASML and Prog cells were seeded on BSA- or LN5 (LN332)-coated plates. Where indicated, cultures 
 55 
contained CoCl2 and/or aprotinin or MMP-Inh.II. Adhesion was measured after 4h. The percentage of 
adherent cells (mean±SD of triplicates) is shown. Significant differences between BSA and LN5: *; 
significant difference of untreated versus CoCl2-treated cells: s; for Aprotinin and MMP-Inh.II 
inhibition p-values are shown.  
While LN5 adhesion decreased with time, hypoxia enhanced migration of 
ASML and Prog cells on LN5 as revealed by in vitro wound healing evaluated 
24 h and 48 h after wounding. In addition, both C4.4 and B5.5 inhibited wound 
closure on LN5-coated plates in the presence or absence of CoCl2 (Fig.12A). In 
line with the MMP-Inh.II-restored adhesiveness to LN5, MMP-Inh.II interfered 
with migration. MMP-Inh.II exerted no or a minor effect on wound healing of 
Prog and ASML cells on BSA, but significantly inhibited wound healing on 






Figure 12: The impact of C4.4A, α6β4 and a protease inhibitor on wound closure. (A-D) 
Subconfluent monolayers of ASML and Prog cells on BSA- or LN5 (LN332)-coated plates were 
scratched and wound closure was controlled in the presence or absence of C4.4 or B5.5 and CoCl2 for 
48h-72h. In (C, D), cultures contained MMP-Inh.II. Wound closure was controlled using an inverted 
microscope. (A, C) Representative images (Scale bar: 50µm) and (B, D) the mean (triplicates) of 
wound closure are shown. Significant differences between BSA and LN5: *; significant difference of 
untreated versus CoCl2-treated cells: s; for antibody and MMP-Inh.II inhibition p-values are shown. 
The increased migratory activity induced by hypoxia also accounted for 
transwell migration of ASML and Prog cells, which was promoted by CoCl2-
treatment and inhibited by C4.4 and B5.5 (Fig.13A). Transwell migration 
towards LN5 was inhibited by MMP-Inh.II, although the effect was weak for 
Prog cells (Fig.13B). 
 
Figure 13: The impact of protease inhibitors on LN5 transwell migration. (A, B) Cells were 
seeded in Boyden chambers, the lower chamber contained RPMI/1%BSA or 804G supernatant. (A) 
Cells were pre-incubated with C4.4, B5.5 or mouse IgG1. (B) Cultures contained MMP-Inh.II. 
Migration was evaluated after 16h. The mean (triplicates) of transwell migrating cells is shown. 
Significant differences between BSA and LN5 (LN332): *; significant difference of untreated versus 
CoCl2-treated cells: s; for antibody and MMP-Inh.II inhibition p-values are shown. 
Taken together, hypoxia supports an association between C4.4A and α6β4. Both 
molecules promote short term LN5 adhesion, but lasting migration. A serine 
protease and an MMP inhibitor restore adhesiveness. Migration is more strongly 
affected by an MMP inhibitor. Thus, hypoxia might be accompanied by 
increased protease activity accounting for LN5 degradation, where LN5 
degradation products can exert chemotactic activity (Giannelli et al., 1997; 
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Koshikawa et al., 2000; Udayakumar et al., 2003). Alternatively, hypoxia might 
contribute to C4.4A shedding or release. These two possibilities are not 
mutually exclusive. 
 
3.5 C4.4A cooperation with proteases 
As a protease inhibitor interfered with ASML and Prog migration, I next tested 
whether under hypoxic condition LN5 becomes degraded and whether C4.4A is 
engaged in this process. ASML (Jung et al., 2009) and Prog cells secrete LN5. 
C4.4A poorly co-localized with LN5 on BSA-coated plates under normoxic 
conditions. Co-localization was promoted, when CoCl2-treated cells were seeded 
on LN5-coated plates (Fig. 14A). However, the experimental setting did not 
allow to judge on LN5 degradation. Therefore ASML and Prog cells were 
seeded in the presence or absence of CoCl2 on uncoated plates, removing cells 
after 2d of culture by EDTA and staining for LN1, LN5 and FN. In CoCl2-
treated cultures the rim staining for LN5 was stronger and more focalized, but 
the area below the cell body was free of LN5. Instead, FN remained deposited 
below the cell body independent of CoCl2-treatment. LN1 deposition was 
reduced, but not abolished. Staining of cell free areas confirmed poor LN5, high 
FN and intermediate LN1 recovery (Fig.14B). 
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Figure 14: Cooperativity of C4.4A and MMP14 in LN5 degradation. (A) ASML and Prog cells 
cultured on LN5 (LN332)-coated cover slides in the absence or presence of CoCl2 were fixed, stained 
with anti-LN5 / anti-mouse-Cy2 (g) and C4.4-TxR (r). Single fluorescence and digital overlays are 
shown. (B) ASML and Prog cells were cultured with or without CoCl2 on glass slides. Cells, cell 
ghosts (EDTA) and areas where cells apparently were removed completely ("cell-free" area), were 
stained with anti-LN2, anti-LN1, anti-FN and Cy3-labeled secondary antibodies. Single fluorescence 
staining is shown (scale bar: 5µm). 
These findings argued for LN5 and (partial) LN1 fragmentation. To control the 
hypothesis, LN1 and LN5 (804G supernatant) were co-cultured for 24h with 
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ASML cells in the presence of CoCl2 with or without MMP-Inh.II. Cells were 
removed and the laminins were separated by SDS-PAGE. Gels were stained 
with Coomassie blue or proteins were transferred and blotted with anti-LN1 or 
anti-LNγ2 (anti-LN5). Coomassie blue staining provided evidence for LN1 and 
LN5 fragmentation, which was reduced, when cultures contained MMP-Inh.II. 
WB confirmed LNγ2 degradations and a weaker LN1 band was recovered, when 
LN1 was co-cultured with CoCl2-treated ASML cells, but not when cultures 
contained MMP-Inh.II (Fig.15). 
 
Figure 15: Cooperativity of C4.4A and MMP14 in LN1/LN5 degradation. ASML cells were 
suspended in 25µg LN1 (LN111) or 250µg 804G supernatant (LN332). Cells were incubated at 37
o
C 
for 16h in the presence of CoCl2 with or without MMP-Inh.II. Cells were removed, supernatants were 
dried, dissolved in lysis buffer and separated by SDS-PAGE. Gels were stained with Coomassie blue 
or after transfer blotted with anti-ratLN1 or anti-ratLNγ2.  
Our data showed that C4.4A might promote motility via associating with 
proteases involved in laminin degradation. According to the inhibitory activity 
of MMP-Inh.II, MMP14 was considered a possible candidate. Weak co-
localization of MMP14 with C4.4A and α6β4 in resting cells became strong, 
when CoCl2-treated cells were grown on LN5-coated slides (Fig.16A), which 
corresponded to an increase in co-immunoprecipitation of C4.4A and α6β4 with 
MMP14 in CoCl2-treated ASML cells. C4.4A and more pronounced α6β4 also 
co-immunoprecipitated TACE, but not uPA, uPAR, MMP2 and MMP9. 
Although the C4.4A and α6β4 association with TACE was CoCl2-treatment 
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Figure 16: The C4.4A association with proteases. (A) ASML and Prog, grown on BSA- or LN5 
(LN332)-coated plates in the presence or absence of CoCl2 were stained with anti-MMP14 / anti-
rabbit-Cy2 (g) and C4.4-TxR (r) or B5.5-TxR (r). Digital overlays are presented (bar size: 5µm). (B) 
Expression of C4.4A, α6β4, uPA, uPAR, TACE, MMP2, MMP9 and MMP14 in untreated and CoCl2-
treated ASML cells. (C) Co-immunoprecipitation of C4.4A and α6β4 with uPAR, TACE, MMP2, 
MMP9 and MMP14. (D) Co-localization of C4.4A and α6β4 with TACE in untreated and CoCl2-
treated ASML and Prog grown on LN5-coated glass slides. Digital overlays of staining with anti-
TACE / anti-rabbit-Cy2 (g) and C4.4-TxR (r) or B5.5-TxR (r) are shown (bar size: 5µm). 
The association of C4.4A with TACE, possibly via α6β4, and the fact that 
C4.4A has a highly sensitive cleavage site (Gårdsvoll et al., 2007) and is 
delivered in exosomes (Paret et al., 2005), prompted us to evaluate, whether 
CoCl2-treatment supports C4.4A cleavage and/or exosomal release.  
 
3.6 Functional activity of cell free C4.4A 
C4.4A is a GPI-anchored molecule, which are located in rafts. Raft proteins are 
known to become internalized and to be recovered and enriched in exosomes, 
which contain functional active proteins. Thus, I next asked whether the C4.4A-
MMP14-α6β4 complex is also present in exosomes. C4.4A is recovered in 
exosomes, a higher amount being recovered from CoCl2-treated cells. Exosomes 
also contain α6β4. Exosomal C4.4A and α6β4 co-immunoprecipitate and also 
maintain the association with MMP14 and TACE, both MMP14 and TACE 
being known to be abundantly recovered in exosomes. I also recovered shed 
C4.4A, but only in the supernatant of CoCl2-treated ASML cells. C4.4A 
shedding is largely abolished in the presence of TAPI. However, TAPI did not 
influence the delivery in exosomes. (Fig.17). 
 
Figure 17: C4.4A recovery in exosomes and in vesicle-depleted culture supernatant. ASML cells 
were cultured in the absence of FCS with or without CoCl2 and TAPI. Supernatant were collected and 
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separated by ultracentrifugation. Vesicle-depleted supernatant and lysed exosomes (20µg) were 
separated by SDS-PAGE, transferred and blotted with C4.4, anti-MMP14 and anti-TACE. In addition, 
precipitates of exosome lysates with C4.4 and B5.5 were separated by SDS-PAGE and after transfer 
blotted with C4.4, anti-MMP14 and anti-TACE. 
These findings raised the question, whether exosomal or shed C4.4A would 
contribute to LN degradation. When exosomes and supernatant from CoCl2-
treated ASML cells were co-incubated with LN1 and LN5 (804G supernatant), 
exosomes, but not shed C4.4A degraded LN1 and LN5 as efficiently as ASML 
cells. Exosomes of CoCl2-treated Colo357 cells were also incubated with LN5 
(A431 supernatant). In comparison to the control (LN5 alone), LN5 is degraded 
by exosomes. LN degradation by exosomes was also inhibited by MMP-Inh.II 
(Fig.18). 
 
Figure 18: Laminin1 and laminin5 degradation by exosomes. Vesicle-depleted supernatant or 
exosomes of CoCl2-treated ASML and Colo357 cells were incubated with 10µg/ml LN111 or 50µg 
804G or A431 supernatant (LN332) in the presence or absence of MMP-Inh.II. After 16h incubation, 
cultures were dried and proteins dissolved in lysis buffer. Samples were separated by SDS-PAGE and 
gels were stained with Coomassie blue or proteins were transferred and stained with anti-ratLN1, -
ratLN2, -humanLN3, -humanLN3 or humanLN2.  
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Only supernatant of CoCl2-treated ASML cells contained shed C4.4A, where 
TACE contributes to C4.4A shedding. Hypoxia strengthens incorporation of the 
functionally active C4.4A-α6β4-MMP14 complex into exosomes, such that LN1 
and LN5 become degraded by exosomes.  
 
3.7 C4.4A contribution to metastasis 
C4.4A can associate with 64 and MMP14, and this complex contributes to 
matrix degradation and increased motility. To confirm the relevance of this 
association on metastasis formation in vivo, we generated a C4.4A
kd
 of the 
highly metastatic ASML line. To generate a C4.4A
kd
, ASML cells were 
transfected with C4.4A siRNA and grown in Neomycin selection medium. 
Neomycin resistant cells were cloned by limiting dilution and tested for C4.4A 
expression by FACS after each recloning step until uniformly positive clones 
were obtained. For all the following experiments, we used clone1 (ASML-
C4.4A
kd1
) which showed a very strong reduction in C4.4A expression (Fig.19A). 
ASML and ASML-C4.4A
kd
 cells, were injected intrafootpad and tumor growth 





 cells transiently developed a small local tumor, but developed lymph 
node metastasis with a significant delay. After 44 days, when all ASML-bearing 
rats had become moribund, ASML-C4.4A
kd
-bearing rats had not developed 
axillary or lung metastasis, which, however, were recovered with delay, when 
ASML-C4.4A
kd
 bearing rats became moribund. Due to the retarded metastatic 
spread, the mean survival time of ASML-C4.4A
kd
-bearing rats was significantly 
prolonged from 39d of ASML-bearing rats to 64d (Fig.19B-19D). 
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Figure 19: Retarded metastasis formation of ASML-C4.4A
kd
 cells. (A) WB of C4.4A in ASML 
and ASML-C4.4A
kd
 cells. EpCAM served as control. (B-D) BDX rats received 1x10
6
 ASML or 
ASML-C4.4A
kd
 cells, ifp. (B) Local tumor growth and growth in draining (popliteal) and distant 
(inguinal, axillary, paraaortic <p.a.>) LN during 6wk after tumor cell application. The mean diameter 
of tumor of 5 rats / group is shown. (C) Survival time and survival rate of ASML and ASML-C4.4A
kd
 
bearing rats (D) Mean survival time of 8 rats / group. 
Immunohistology of local tumors, lymph node and lung metastasis, excised at 
late stages of tumor growth, confirmed a distinct growth profile of ASML and 
ASML-C4.4A
kd
 cells. While ASML cells grow dispersed between host cells, the 
ASML-C4.4A
kd
 cells form tumor clusters that do not penetrate the surrounding 
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tissue (Fig.20A-20B). In addition, ASML-C4.4A
kd
 tumors were rich in LN1 and 
LN5, particularly at the rim of the tumor nodules. Instead, LN1 and LN5 










injection. (A) Immunohistology of the local tumor, popliteal LN, lung and muscle metastasis of 
ASML and ASML-C4.4A
kd
-bearing rats stained for the ASML markers C4.4A, EpCAM, D6.1A 
(Tspan8) and CD44v6 and (B) The popliteal node was stained with the leukocyte markers CD4, CD8 
CD11b, sIgM and a granulocyte marker as well as with the endothelial marker CD31. (C) 
Immunohistology (popliteal LN) of the matrix proteins LN1 (LN111), LN5 (LN332), Coll I and Coll 
IV. (Scale bar: 100µm). 
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Thus, metastasis formation of ASML-C4.4A
kd
 cells is delayed and their capacity 
to invade surrounding tissue, including vessel endothelium, is strongly affected. 
This may be due to encapsulation by matrix proteins.  
 
3.8 Motility / invasiveness reduction of ASML-C4.4A
kd
 cells is a sequel of 
impaired focalization of 64 and MMP14  
We have shown before that upon stimulation C4.4A associates with 64 and 
MMP14, which promotes LN1 and LN5 degradation. Instead, when ASML-
C4.4A
kd
 cells were seeded on LN1 or LN5 in the presence of PMA, 64 and 
MMP14 hardly co-localize (Fig 21A). Furthermore, only ASML, but not 
ASML-C4.4A
kd
 cells degraded LN1 and LN5, where degradation was inhibited 
in the presence of a broad range MMP inhibitor (Fig.21B). 
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Figure 21: Cooperation of 64 and MMP14 in ASML-C4.4Akd cells. (A) ASML and ASML-
C4.4A
kd
 cells were seeded on LN5 (804G supernatant)-coated slides. Cells were double stained with 
C4.4A and 64 or MMP14 or with 64 and MMP14. Single fluorescence staining and digital 
overlays are shown (scale bar: 5µm). (B) ASML and ASML-C4.4A
kd
 cells were cultured overnight in 
the presence of PMA or DMSO (control) and MMP-InhII on glass cover slides. Cells were stained 
with anti-LN2. The standard exposure and overexposure are shown. 
The failure of ASML-C4.4A
kd 
cells to recruit MMP14 towards 64 for LN 
degradation had severe consequences on cell migration. Transwell migration of 
ASML-C4.4A
kd
 cells was significantly reduced compared to ASML cell 
migration and was hardly inhibited by B5.5 (anti-64). Furthermore, an MMP 
inhibitor had no effect on ASML-C4.4A
kd 
migration, whereas it strongly 
inhibited ASML
wt 
migration. A TACE inhibitor exerted no effect on both cell 
lines (Fig.22A, 22B). 
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Figure 22: Impact of protease inhibitors on ASML-C4.4A
kd
 cell migration. (A) ASML and 
ASML-C4.4A
kd
 cells were untreated or PMA-treated and seeded in the upper part of a Boyden 
chamber. The lower chamber contained LN5 in RPMI/20%FCS. Where indicated cells were pre-
incubated with C4.4 or B5.5. Migration was evaluated after 16h by staining the lower membrane site 
with crystal violet. The percent migrating cells (mean of triplicates) is shown. Significant differences 
between ASML and ASML-C4.4A
kd
 cells: *, significant antibody inhibition of migration: s. (B) 
ASML and ASML-C4.4A
kd
 cells were incubated with TAPI (TACE inhibitor) or MMP-InhII (MMP14 
inhibitor) and seeded in the upper part of a Boyden chamber. Migration was evaluated as above. 
Significant differences between ASML and ASML-C4.4A
kd
 cells: *, significant differences in the 
presence of the inhibitors: s. 
The cooperativity between C4.4A and 64 was also confirmed in an in vitro 
wound healing assay, where C4.4 and B5.5 inhibited ASML cell migration, but 
neither antibody inhibited the poor migration of ASML-C4.4A
kd





Figure 23: Impact of anti-64 on wound healing of ASML-C4.4Akd cells. ASML and ASML-
C4.4A
kd
 cells were seeded in 24-well plates coated with BSA, LN111 or LN223. (A, B) When 
reaching subconfluence, the monolayer was scratched. Wound healing was evaluated for 72h by light 
microscopy. Where indicated, the cultures contained C4.4 or B5.5. (A) A representative example and 
(B) the mean % of wound closure are shown. Significant differences between ASML and ASML-
C4.4A
kd
 cells: *; significant differences between control IgG, C4.4 and B5.5: s. (Scale bar: 50µm) 
Taken together, co-localization of 64 and MMP14 is reduced in PMA-
stimulated ASML-C4.4A
kd
 cells. This is accompanied by a reduction in LN5 
degradation and in migratory activity.  
 
3.9 Impaired drug resistance of ASML-C4.4A
kd
 cells 
To control whether the retarded tumor growth is due only to impaired motility, a 
second in vivo experiment was performed, where tumor cells were injected 
intraperitoneally such that at least intraperitoneal tumor growth should not be 










with 37±9.7 days significantly. Furthermore, while the 
survival time of ASML
wt




-bearing rats are still alive 
(Fig.24). 
 
Figure 24: Cisplatin susceptibility of ASML-C4.4A
kd
 cells: BDX rats received 5x10
6
 ASML or 
ASML-C4.4A
kd
 cells, ip. After 2 and 23 days, they received 1µg/kg cisplatin, ip. (A) Survival time 
and rate of 5 rats / group; (B) Mean survival time. Significant differences between ASML and ASML-
C4.4A
kd
- bearing rats or ASML-cisplatin and ASML-C4.4A
kd 
-cisplatin-bearing rats : * 
One possible reason could have been a loss in apoptosis resistance, where it 
should be noted that ASML
wt
 are known to be extremely apoptosis resistant 
(Matzku et al.,1983; Klingbeil et al., 2009). To control for the hypothesis, I 
evaluated apoptosis resistance in vitro in the presence of cisplatin. In fact, 
7.5µg/ml cisplatin sufficed for a 50% reduction of the proliferative activity of 
ASML-C4.4A
kd
 cells as compared to ASML
wt
 cells, which required 20µg/ml 
cisplatin. Similar effects were seen evaluating the percentage of apoptotic cells 





 cells was even more striking, evaluating anchorage-
independent growth. Only 0.6% of ASML-C4.4A
kd
 cells, but 30% of ASML
wt
 
cells formed colonies in the presence of 1µg/ml cisplatin (Fig.25A-25D). 
 74 
 
Figure 25: Reduced apoptosis resistance of ASML-C4.4A
kd
 cells. (A-D) ASML and ASML-
C4.4A
kd
 cells were cultured with titrated amounts of cisplatin. (A) 
3
H-thymidine incorporation, (B) 
AnnexinV/PI staining, (C, D) soft agar colony formation. (C) Representative example. (D) Mean ± SD 
of colonies in soft agar. Significant differences in cisplatin resistance between ASML and ASML-
C4.4A
kd
 cells: *  
ASML-C4.4A
kd
 cells show a significant decrease in apoptosis resistance, most 
strongly in anchorage-independent growth.  
To evaluate the underlying mechanism, I started to control for caspase 
activation, where caspase 8 is triggered by death receptors. Caspase 9 and 
caspase 3 become activated downstream of caspase 8 or via the mitochondrial 





 cells provided clear evidence for unaltered caspase 8 activity, 
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but a strong upregulation of cleaved caspase 9 and activated caspase 3 in 
cisplatin-treated ASML-C4.4A
kd
 cells (Fig. 26). 
 




 cells. ASML and ASML-C4.4Akd cells 
were cultured in the presence or absence of cisplatin (10µg/ml). Cells were stained with anti-caspase 
8, -cleaved caspase9 and -activated caspase 3 and the appropriate secondary antibody. Expression was 
evaluated by FACS. Significant differences in caspase activity between cisplatin-treated ASML and -
ASML-C4.4A
kd
 cells: *   
This finding excludes receptor-mediated apoptosis accounting for the 
pronounced cisplatin sensitivity of ASML
wt 
cells. The definition of changes in 
the mitochondrial pathway of apoptosis remains to be specified. 
In brief, C4.4A expression is regulated by stress, including hypoxia. It 
contributes to cell motility by associating with 64 in rafts and by forming a 
complex with MMP14. Thereby, MMP14 becomes triggered to degrade LN5, 





line provided additional evidence for a contribution of 
C4.4A to apoptosis resistance. The deficiency of C4.4A does not affect death 
receptor-mediated apoptosis, but rather the mitochondrial pathways of apoptosis 
resistance. Loss of apoptosis resistance in ASML-C4.4A
kd
 cells may also well 
rely on the failure to recruit 64 towards raft located C4.4A.  
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4. DISCUSSION  
The metastatic cascade demands particular features from a tumor cell. Besides 
of the capacity to isolate from the primary tumor mass, migratory, as well as 
adhesion features are required. Tumor cells should have invasive potential and 
be apoptosis resistant to survive in the isolated state and in the foreign 
environment (Mina and Sledge, 2011).  
C4.4A is a metastasis-associated protein, which was first identified in a screen 
designed to select membrane proteins that were differentially expressed by 
highly metastasizing rat pancreatic cell lines (Claas et al., 1996; Matzku et al., 
1989). The function of metastasis-associated C4.4A, with very restricted 
expression in normal tissue (Rösel et al., 1998; Würfel et al., 2001; Hansen et 
al., 2004; Claas et al., 1996; Smith et al., 2001), remains elusive (Jacobsen et 
al., 2008). Nonetheless, circumstantial evidence has prompted speculations that 
C4.4A, which is a receptor for LN1 and LN5, may be involved in either cell-
matrix interactions (Rösel et al., 1998; Smith et al., 2001; Paret et al., 2005) or 
in cell-cell adhesion (Hansen et al., 2008).  
Invasion and metastasis are the major characteristics of malignant tumors (Ryu 
et al., 2010), where one of the common features is a state where oxygen tension 
drops below normal limits (Vaupel et al., 2004). Here, we report that hypoxia-
induced C4.4A up-regulation promotes transition from a sessile towards a 
mobile phenotype through pronounced association with the integrin α6β4 and 
proteases, where the latter strengthens motility by focalized matrix degradation. 
Motility and invasiveness are further strengthened by the release of a C4.4A-
α6β4-MMP14 complex into exosomes, which extends the range of matrix 
degradation as exosomes are known to contain functionally active proteins 
(André et al., 2002; Zöller, 2006; Schorey and Bhatnagar, 2008). 
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After having explored the functional consequences of C4.4A up-regulation 
under hypoxia, I controlled these findings in a knock down C4.4A in a 
metastasizing tumor cell line created by the siRNA approach. In vitro and in 
vivo studies confirmed the involvement of C4.4A in cell motility and 
invasiveness. In addition, the C4.4A knockdown provided evidence that C4.4A 
also contributes to apoptosis/cytotoxic drug resistance.  
Thus, there is strong evidence that C4.4A acts as a metastasis supporting 
molecule. However, none of the described features are genuine characteristics of 
C4.4A. Instead, C4.4A co-ordinates the association with α6β4 and MMP14. 
α6β4 promotes motility and apoptosis resistance. MMP14 facilitates matrix 
degradation and invasiveness. I will discuss, how C4.4A binding to LN1 and 
LN5 acts as a linker that co-ordinates several steps in the metastatic cascade.  
 
4.1 Regulation of C4.4A expression in hypoxia 
Low oxygen level and, as a surrogate, CoCl2-treatment (Liu et al., 1999), are 
accompanied by HIF1α accumulation, that becomes transported to the nucleus, 
where it acts as a transcription factor for multiple genes (Yee et al., 2008; 
Brahimi-Horn and Pouysségur, 2009). Several studies have shown that hypoxia 
causes HIF1α accumulation in several human malignancies. I first demonstrated 
that hypoxia is accompanied by up-regulated C4.4A expression. As the C4.4A 
promoter contains 3 HRE, we considered the possibility that HIF1α may 
contribute to C4.4A transcription by binding to the HRE to drive its 
transcription. However, co-transfection with HIF1α expression vector as well as 
transfection with the C4.4A promoter bearing the HRE mutation, did not 
provide evidence for HIF1α contributing to C4.4A transcription. C/EBPβ, 
essentially required for C4.4A transcription (Fries et al., 2007), has also been 
associated with metastasis-associated gene transcription (Chun et al., 2004), 
gene expression in differentiating keratinocytes and during wound repair 
 78 
(Maytin et al., 1999; House et al., 2010). However, we did not observe 
significantly up-regulated C4.4A transcription in CoCl2-treated cells. Thus, 
hypoxia-induced high C4.4A expression may be a consequence of stabilized 
protein expression or increased expression of its associated partners. The finding 
that CoCl2-treatment does not induce expression in C4.4A-negative tumor lines 
is in line with this interpretation. Nonetheless, hypoxia is accompanied by an 
increase in C4.4A expression, which allowed me to proceed in evaluating its 
functional activities.  
 
4.2 Cooperation of C4.4A with α6β4 and MMP14 
C4.4A expression becomes strongly up-regulated in migrating keratinocytes 
during wound repair (Paret et al., 2007) and a direct contribution to keratinocyte 
migration has been demonstrated by anti-C4.4A antibody significantly inhibiting 
wound healing. In vitro, CoCl2-treatment promoted migration of C4.4A
+
 tumor 
cells on LN5, a major C4.4A ligand (Paret et al., 2005), after a transient increase 
in LN5 adhesion. 
The engagement of C4.4A in the shift towards motility on LN5 relies on 
hypoxia-induced associations of C4.4A with α6β4 and MMP14. On LN5, but 
not on BSA, C4.4A co-localizes and associates with α6β4, focalized co-
localization and association being stronger under hypoxia. LN5 is a major ligand 
for α6β4 (Rabinovitz , Mercurio et al., 1996; Kariya et al., 2009) and one could 
have speculated that C4.4A only acts as an accessory molecule. This has been 
excluded as recombinant C4.4A binds LN5 (Paret et al., 2005) and AS1B1 cells, 
which do not express α6β4 (Rösel et al., 1998), also show pronounced LN5 
binding. Finally, adhesion and migration on LN5 became equally well inhibited 
by C4.4 and anti-α6β4. Whether C4.4A recruits α6β4 or vice versa or whether 
α6β4 and C4.4A come into vicinity via their joint ligand(s), remains to be 
explored.  
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Though LN5 can account for stable anchoring contacts through interaction with 
α6β4 and the β4 chain-initiated recruitment of collagen XVII and plectin 
(Litjens et al., 2006), LN5 also stimulates directed cell migration (Guess and 
Quaranta, 2009) mostly through rac1 activation (Pullar et al., 2006). Thus, the 
C4.4A-α6β4 association and joint binding to LN5 can well account for increased 
migration during hypoxia. Migration-promoting activity of LN5 is also 
strengthened by proteolytic processing (Marinkovich et al., 1992), where the rat 
LNγ2 chain is cleaved by MMP2 and MMP14 (Koshikawa et al., 2000; 
Giannelli et al., 1997). One of the γ2 fragments activates the EGFR (Schenk et 
al., 2003). Different LN5 fragments from the γ2 and the α3 chain also account 
for the deposition of LN into the matrix underlying cultured cells (Gagnoux-
Palacios et al., 2001; Sigle et al., 2004). MMP14 and MMP7 can also cleave the 
β3 chain (Udayakumar et al., 2003; Remy et al., 2006); the α3 chain can be 
cleaved by several proteases including plasmin (Ogura et al., 2008). Three 
observations are in line with hypoxia-induced C4.4A up-regulation accounting 
for pronounced migration due to LN5 fragmentation: (i) broad serine or MMP 
inhibitors promoted LN5 adhesion; (ii) LN5 deposits were not recovered in 
CoCl2 treated cultures; (iii) an MMP inhibitor strongly reduced migration on 
LN5. As aprotinin partially restored adhesion to LN5, but MMP-Inh.II exerted 
stronger effects on cell migration, we tested several proteases for associating 
with C4.4A. C4.4A does not associate with uPAR, uPA, MMP2 or MMP9, but 
associates with TACE/ADAM17 and, more strongly in hypoxia with MMP14. 
The fact that C4.4A can be cleaved by TACE (Esselens et al., 2008) and LN5 
can be degraded by MMP14 (Tsuruta et al., 2008) is in conformity with the 
association of C4.4A with TACE and MMP14.  
The association of C4.4A with α6β4 and MMP14, which allows for focalized 
LN5 fragmentation that can promote directed motility, provides a first 
explanation for the activity of C4.4A in tissue remodeling, wound repair and 
tumor progression. 
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4.3 Hypoxia and C4.4A release 
C4.4A shedding and exosomal release (Paret et al., 2007) are both stimulated 
under stress, including hypoxia. Soluble C4.4A has only been detected under 
hypoxia and could be linked to C4.4A cleavage by TACE/ADAM17, as already 
reported (Esselens et al., 2008). The increase in exosomal C4.4A corresponds to 
a pronounced exosome release under stress (Simons et al., 2009). In line with 
the internalization of membrane microdomains, such that internalized protein 
complexes remain intact (Staubach et al., 2009), exosomes collected from 
CoCl2-treated tumor cells contained C4.4A, α6β4 and MMP14, where for the 
latter clathrin- and caveolin-dependent internalization has been described (Jiang 
et al., 2001). Exosomal proteins are functionally active (Escrevente et al., 2008), 
which also accounts for MMP14 (Hakulinen et al., 2008). In fact, the exosomal 
C4.4A-α6β4-MMP14 complex, but not soluble C4.4A suffices for LN5 
degradation. These findings uncovered two important points. First, the activity 
of the C4.4A-α6β4-MMP14 complex is not restricted to the cell membrane, but 
can additionally prepare the surrounding of migrating epithelial and tumor cells, 
thus extending the operational range of C4.4A. Second, the finding that shed 
C4.4A does not degrade LN5 confirms that not C4.4A by itself, but a complex 
of C4.4A with proteases is required for LN5 fragmentation.  
Taken together, C4.4A up-regulation induced by hypoxia is accompanied by 
transiently increased LN5-adhesion and pronounced migration. LN5 adhesion 
and migration are supported by the strong C4.4A-α6β4 association under 
hypoxia. The shift towards migration becomes facilitated by focalized LN5 
degradation by membrane-bound and exosomal C4.4A-associated MMP14. The 
recovery of a functionally active C4.4A-α6β4-MMP14 complex in exosomes 
adds to the functional relevance of C4.4A in wound healing, tissue remodeling 
and tumor cell spread. 
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4.4 The impact of C4.4A on metastasis formation 
C4.4A has originally been detected on a metastasizing rat adenocarcinoma 
(Matzku et al., 1989; Claas et al., 1996) and thereafter has been detected in 
several human cancer, where C4.4A expression frequently was more 
pronounced or even restricted to metastatic tissue (reviewed in Jacobsen and 
Ploug, 2008). However, when a non-metastasizing subline of the rat pancreatic 
adenocarcinoma, the AS line was transfected with C4.4A, it did not metastasize 
after subcutaneous application, whereas after iv injection AS as well as AS-1B1 
cells grow in the lung. Distinct to AS cells, AS-1B1 tumors do not form a 
fibrous capsule and grow aggressively with destruction of bronchioli and vessel 
walls. The findings with the ASML-C4.4A
kd
 are in line with these features. 
ASML-C4.4A
kd
 cells are still capable to metastasize via the lymphatic system, 
albeit with a significant delay. However, the growth profile of ASML-C4.4A
kd
 
tumors differs from that of ASML
wt
 tumors in several aspects: (i) the tumor 
grows locally before metastases develop; (ii) the local tumor and metastases 
have a fibrous capsule; (iii) in line with this, no dispersed tumor cells are 





 cells show well developed tumor vessels. 
The local growth, the fibrous capsule, the failure to invade the surrounding 
tissue and the recovery of intact vessels in tumors could well rely on the 
association of C4.4A with MMP14 and, only under stress conditions, the 
recruitment of α6β4 towards the raft located C4.4A. 
I already described that stress-induced activation of C4.4A supports the 
proteolytic activity of MMP14. Thus low C4.4A expression in ASML-C4.4A
kd
 
cells obviously does not suffice for MMP14 activation and hence, LN 
degradation is decreased. MMP14 also account for MMP2 activation (Holmbeck 
et al, 2004), which predominantly degrades collagens (Schneider et al, 2008). 




 tumor. Undisturbed encapsulation of ASML-C4.4A
kd
 tumors, in turn, 
explains that the tumor cells do not penetrate into the surrounding tissue. 
Though the better vascularization of ASML-C4.4A
kd
 tumors could be a response 
to the demand of the solid tumor mass for oxygen, we consider it more likely 
that the poor vascularization of ASML
wt
 tumors is a consequence of 
overshooting matrix degradation, thus destroying the path for sprouting 
capillary. This will not take place in ASML-C4.4A
kd
 tumors. The presence of 
short capillary fragments in the ASML
wt
 tumor supports our interpretation. 
Taken together, although we did not recover any direct functional activity of 
C4.4A besides binding to LN5, LN1 and galectin3 (Paret et al., 2005), by its raft 
localization and the activation induced recruitment of 64 as well as the 
associated activation of raft-located MMP14, C4.4A becomes central in 
coordinating tumor cell motility and invasiveness. The finding that in 
esophageal cancer C4.4A expression is reduced at early stages of tumor growth 
and becomes upregulated during metasasis formation (Hansen et al, 2008), 
supports the concept of a tightly regulated expression that selectively supports 
migration and invasion of isolated or leading front tumor cells by associating 
with activated 64 and MMP14, which allows for cytoskeleton reorganization 
and for creating space, where LN5 track formation (Sehgal et al., 2006) as well 
as short fragments of LN3 (Decline and Rousselle, 2001) can strengthen 
motility. 
 





 tumor cells are highly susceptible 
to cisplatin, which in vivo allows for a significant prolongation of the survival 
time. We used cisplatin as a therapeutic at a relatively low dose that does not 
exert cytotoxic side effects. In the absence of cisplatin, there has been no 
evidence for reduced apoptosis resistance of ASML-C4.4A
kd




 cells. This again pointed towards a stress situation, where C4.4A 
becomes engaged in apoptosis resistance, which has been confirmed in vitro, 
where a strikingly upregulation of cleaved caspase 9 and activated caspase 3 
with unaltered caspase 8 activity has been seen in cisplatin-treated ASML-
C4.4A
kd
 cells. Thus, it is the mitochondrial apoptosis pathway (Strasser et al., 
2011) that is triggered in stressed ASML-C4.4A
kd
 cells. 
Having experienced that C4.4A becomes engaged in motility and invasiveness 
via its association with 64, we speculated that the association with 64 may 
also contribute to apoptosis resistance. The hypothesis has been supported by 
our previous finding that in ASML
wt
 cells, apoptosis resistance, due to high level 
anti-apoptotic protein expression is triggered via CD44v6, but can be initiated 
via CD44, 64 or Met ligand binding. Activation of anti-apoptotic molecules 
downstream of CD44v6 mostly proceeded via activation of the MEK signaling 
cascade (Jung et al., 2011). However, preliminary experiments did not reveal 





cells. Instead there is evidence for strongly diminished 
activation of the PI3K/Akt pathway in ASML-C4.4A
kd 
cells. PI3K/Akt 
activation by 4 in cancer has been described by several groups (Giancotti, 
2007; Nguyen et al., 2000; Shaw et al., 1997; Hintermann et al., 2001; Santoro 
et al., 2003; Trusolino et al., 2001), where 64 clustering by LN5 can be the 
initial trigger (Nguyen et al., 2000; Kippenberger et al., 2004). In line with the 
latter observation, the intracellular tail of 4 does not suffice for Akt activation. 
Also, it is unlikely that PI3K becomes directly activated by phosphorylated 4 
(Merdek et al., 2007). Several pathways for 4 activation have been described. 
Besides activation via associated growth factors (Hintermann et al., 2001; 
Trusolino et al., 2001) or via insulin receptor substrate 1 and 2 (Kippenberger et 
al., 2004), raft recruitment and the interaction with raft-located tyrosine kinases 
are considered to provide the initial trigger (Giancotti, 2007). Our preliminary 
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data point towards raft recruitment as the most likely pathway according to the 
constitutive raft localization of C4.4A, the stimulation of 64 via LN5 and the 
recruitment of activated 64 via the joint LN5 ligand. 
Thus, activation of anti-apoptotic molecules appears to be, at least, the 
dominating pathway of apoptosis resistance. Notably, C4.4A again acts as a 
linker without actively contributing to apoptosis resistance. Irrespective of this, 
strong downregulation of C4.4A has a striking effect on the loss of drug 
resistance in vitro as well as in vivo.  
 
Taken together, a C4.4A
kd
 in a metastasizing tumor line confirmed our studies 
on C4.4A overexpression in a non-metastatic line (Rösel et al., 2002) as well as 
the in vitro analysis of C4.4A cooperativity-based actions. By its raft location, 
by binding to LN5, by associating with MMP14 and by recruiting α6β4 under 
stress conditions, C4.4A, though not essentially required for metastasis 
formation, plays an important role in tumor progression allowing tumor cells to 
disperse in the invaded organs and to become cytotoxic drug insensitive. Taking 
the selected steps in the metastatic cascade with a contribution of C4.4A, it 
appears of pathophysiological economy that C4.4A becomes selectively 
upregulated during wound repair and metastatic spread. 
 
4.6 Conclusion 
C4.4A is a metastasis-associated molecule expressed in several types of cancer 
with upregulated expression during tumor progression, as well as during tissue 
remodeling. Though being related to uPAR, there is no evidence for enzymatic 
activity of C4.4A and the function of C4.4A still remains elusive. The aim of my 
thesis was to shed some light on possible pathways of C4.4A activity. 
C4.4A being frequently upregulated under hypoxic conditions, I speculated that 
HIF1α might trigger C4.4A transcription, particulary because the C4.4A 
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promoter contains HIF responsive elements. Though this has not been the case, I 
progressed during the first part of my thesis with evaluating C4.4A activity 
under hypoxic conditions, as hypoxia can well account for stress in a more 
general sense and hypoxia promoted C4.4A upregulation. These in vitro studies 
supported by an in vivo wound healing experiment revealed that C4.4A, which is 
a receptor for LN1 and LN5, exerts fuctional activity mostly via associating 
molecules, where α6β4 and MMP14 play a dominant role. By associating with 
activated α6β4, likely via the joint LN5 ligand, C4.4A promotes motility. 
Motility becomes strengthened by the association with MMP14, which has a 
strong impact on laminin degradation. It is particulary worthwhile noting that 
the raft located C4.4A-α6β4-MMP14 complex becomes internalized and is 
recovered in exosomes in a fuctionally active form, where the exosomal C4.4A-
α6β4-MMP14 complex allows for matrix degradation even in the surrounding of 
C4.4A expressing epithelial cells. C4.4A also gets shed by TACE. But so far, 
possible functional activities of shed C4.4A have not been uncovered.  
In the second part of my thesis, I controlled whether these features of C4.4A are 
of relevance for the metastasis process. To achieve this goal, I generated a 
C4.4A knock down of the highly metastatic ASML line. In vitro and in vivo 
experiments with this line confirmed the results of C4.4A activity under 
hypoxia. Thus, ASML-C4.4A
kd
 cells can metastasize but with significant delay 
and in vitro their migratory activity is strongly reduced. There is evidence that 
this a sequel of reduced α6β4 recruitment towards rafts and impaired MMP14 
activation. The ASML-C4.4A
kd
 line provided evidence for a second major 
activity of C4.4A that has not been uncovered in hypoxia. C4.4A is engaged in 
apoptosis resistance. Our experiments exclude an involvement of C4.4A in 
receptor mediated apoptosis, but point towards C4.4A supporting anti-apoptotic 
molecule expression. This hypothesis remains to be experimentally proven, 
which includes our suggestion on a dominating role of the C4.4A-α6β4 
complex.  
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Taken together, the failure to define the function of C4.4A, so far, likely is due 
to C4.4A predominantly acting as a linker molecule. Without question, α6β4 is 
the most important partner, where C4.4A will recruit activated (α6)β4 via their 
joint LN5 ligand, such that cell motility and apoptosis resistance signaling 
pathways become activated. The second important C4.4A partner is MMP14 
that further strengthens motility of C4.4A expressing cells by LN degradation. 
Finally, I want to stress the point that even suggesting that C4.4A acts mostly as 
a linker, its "linker" activity is essential as motility, invasiveness and apoptosis 
resistance are severely impaired in ASML-C4.4A
kd 
cells. 
C4.4A has a very restricted expression in non-transformed cells. Thus, I suggest 
that based on the presented studies, therapeutic interference with tumor 
progression could be possibly approached via a blockade of C4.4A. 
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5. SUMMARY 
C4.4A was first identified in a screening designed to select metastasis-associated 
membrane proteins. Its expression is very restricted on normal tissue, but 
strongly upregulated during wound healing and progression in some tumors. The 
function of the molecule still remaining elusive, I aimed to shed some light on 
its transcriptional regulation and possible functions. 
As wound repair and tumor growth are frequently associated with a state of 
hypoxia, it became tempting to speculate that hypoxia may promote C4.4A 
transcription. Moreover, the C4.4A promoter contains 3 HIF1 responsive 
elements (HRE), HIF1 being one of the most important transcription factors 
for hypoxia-regulated genes. However, C4.4A promotor activity was not altered 
after mutating the HRE or by co-transfection with HIF1. Nevertheless, hypoxia 
is accompanied by an increase in C4.4A protein expression. Thus, hypoxia 
appeared a suitable model to evaluate functional activities of C4.4A, which I 
evaluated mostly in ASML cells, a metastasizing pancreatic adenocarcinoma 
line. 
In vivo, C4.4A expression becomes strongly up-regulated in migrating 
keratinocytes during wound repair. In vitro, migration of C4.4A positive tumor 
cells on laminin 5 was strengthened under CoCl2-treatment that served to mimic 
a hypoxic state. This relies on hypoxia-induced associations of C4.4A with α6β4 
and MMP14. Migration-promoting activity of laminin 5 is further strengthened 
by its proteolytic processing via MMP14. Thus, the association of C4.4A with 
α6β4 and MMP14 allows for focalized laminin 5 fragmentation that promotes 
motility. 
It is known that C4.4A can become shed, but also be recovered in exosomes. 
Both C4.4A shedding and exosomal release are stimulated under hypoxic stress. 
In line with the internalization of membrane microdomains, exosomes collected 
from CoCl2-treated tumor cells contained the complex of C4.4A with α6β4 and 
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MMP14. Accordingly, the exosomal C4.4A-α6β4-MMP14 complex contributed 
to laminin 5 fragmentation, thus preparing a path for migrating epithelial and 
tumor cells. 
To confirm the relevance of the association of C4.4A with 64 and MMP14 on 
metastasis formation, I generated a C4.4A knockdown of the highly metastatic 
ASML line. Distinct to ASML cells, ASML-C4.4A knockdown (ASML-
C4.4A
kd
) cells metastasize with a significant delay and do not invade 
surrounding tissue. The differences in the growth profile between ASML and 
ASML-C4.4A
kd
 cells could well rely on the association of C4.4A with MMP14 
and, only under stress conditions, the recruitment of α6β4 towards the raft 
located C4.4A.  
The ASML-C4.4A
kd
 cells revealed an additional activity of C4.4A that had not 
been observed before. ASML-C4.4A
kd 
cells were highly cisplatin susceptible, 
whereas there has been no evidence for reduced apoptosis resistance of ASML-
C4.4A
kd
 in the absence of cisplatin. So far, I excluded receptor-mediated 
apoptosis induction, but the pathway accounting for the contribution of C4.4A to 
drug resistance remains to be explored. 
Taken together, my studies confirmed the engagment of C4.4A in epithelial and 
tumor cell motility and invasiveness and provided for the first time a possible 
explanation by unravelling the linker function of C4.4A in recruiting 64 and 
activating MMP14. The novel finding of an engagement of C4.4A in drug 
resistance requires further exploration, that might open a pathway for 
therapeutically attacking metastases via C4.4A. 
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5. ZUSAMMENFASSUNG 
C4.4A wurde bei einer Suche nach metastasierungsrelevanten Membranprotei-
nen der Ratte entdeckt. Es zeichnet sich durch restringierte Expression im 
Normalgewebe aus, wird aber während der Wundheilung und bei einigen Tumo-
ren, speziell während der Metastasierung, überexprimiert. Die Funktion von 
C4.4A ist weitgehend ungeklärt. Das Ziel meiner Arbeit war die Untersuchung 
der transkriptionellen Regulation und möglicher Funktionen. von C4.4A. 
Da Wundheilung und Tumorwachstum in der Regel mit Hypoxie einhergehen, 
wurde zunächst die Möglichkeit einer Hypoxie-induzierten C4.4A-Transkription 
untersucht. Da der C4.4A-Promotorbereich drei HIF1-Erkennungsmotive ent-
hält und HIF1 einer der wichtigsten Transkriptionsfaktoren für Hypoxie-regu-
lierte Gene ist, habe ich die Regulation der Transkription von C4.4A durch Hy-
poxie und HIF1 untersucht. Die C4.4A-Promotoraktivität änderte sich nicht 
durch die Einführung von Mutationen in die HIF1-Erkennungsmotive oder 
durch Transfektion mit HIF1. Dennoch wurde unter Hypoxie ein Anstieg der 
C4.4A-Proteinexpression beobachtet. Daher erschien Hypoxie ein gutes Modell-
system zur Evaluierung funktioneller Aktivitäten des C4.4A-Proteins. Ich habe 
dies bei der in vivo Wundheilung und hauptsächlich in der stark metatasierenden 
Ratten-Pankreasadenokarzinom-Zelllinie ASML untersucht. 
Die C4.4A-Expression wird in migrierenden Keratinozyten während der Wund-
heilung in vivo hochreguliert. In vitro wird die Migration von C4.4A-positiven 
Tumorzellen auf Laminin 5 unter CoCl2-Behandlung, die zu einem Hypoxie-
ähnlichen Zustand führt, verstärkt. Dies ließ sich auf eine Hypoxie-induzierte 
Assoziation von C4.4A mit dem Integrin 46 und MMP14 zurückführen. Die 
migrationsfördernde Aktivität von Laminin 5 wurde hierbei durch den proteoly-
tischen Verdau von Laminin 5 mittels MMP14 verstärkt. Dies bedeutet, daß die 
Assoziation von C4.4A mit 46 und MMP14 lokal die Fragmentierung von 
Laminin 5 und damit Motilität fördert. 
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Es ist bekannt, daß die extrazellulären Domänen von C4.4A abgespalten werden 
können und C4.4A auf Exosomen angereichert ist. Sowohl das C4.4A-Shedding 
als auch die exosomale Freisetzung werden durch Hypoxie stimuliert. Auch der 
C4.4A-46-MMP14-Komplex konnte auf Exosomen von CoCl2-behandelten 
Zellen nachgewiesen werden. Entsprechend dem membranständigen Komplex, 
kann der exosomale C4.4A-46-MMP14 Komplex Laminin 5 verdauen und 
somit die Migration von Epithelzellen und Tumorzellen unterstützen. 
Um die in vivo Relevanz des C4.4A-46-MMP14-Komplexes zu untersuchen, 
habe ich ASML-C4.4A
kd
-Zellen generiert. Im Vergleich zu ASML-Zellen meta-
stasieren ASML-C4.4A
kd
-Zellen signifikant verzögert und dringen nicht in um-
gebendes Gewebe ein. Vorläufige Ergebnisse weisen daraufhin, daß die Unter-
schiede im Wachstumsverhalten der ASML-C4.4A
kd
-Zellen auf die fehlende 
Assoziation von C4.4A mit MMP14 zurückzuführen sind. Hinzu kommt, daß 
auch unter Streßbedingungen die Rekrutierung von 46 in Rafts, in denen 
C4.4A und MMP14 lokalisiert sind, signifikant beeinträchtigt ist. 
Darüber hinaus zeigen ASML-C4.4A
kd
-Zellen eine weitere Besonderheit. Die 
Chemoresistenz von ASML-C4.4A
kd
-Zellen ist im Vergleich zu ASML-Zellen 
deutlich reduziert. Eine Involvierung von C4.4A in Apoptoseresistenz war bis-
her nicht bekannt. Ich konnte rezeptorvermittelte Apoptoseinduktion ausschlie-
ßen. Die zugrundeliegenden Signalwege müssen noch geklärt werden. 
Meine Untersuchungen bestätigten die Beteiligung von C4.4A an der Motilität 
von Epithel- und Tumorzellen sowie der Invasivität von Tumorzellen. Sie lie-
fern darüber hinaus erstmals eine mögliche Erklärung über die C4.4A-vermit-
telten Rekrutierung von 46 und die Aktivierung von MMP14. Erste Befunde 
zu C4.4A-vermittelter Chemoresistenz erfordern weitere Untersuchungen, die 
möglicherweise therapeutische Optionen eröffnen den Metastasierungsprozeß 
über C4.4A zu attackieren. 
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